JP2018109026A - Easily swallowable solid preparation - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an easily swallowable preparation for oral administration with improved swallowing properties, and/or a coating composition used for an easily swallowable preparation with improved eluting properties.SOLUTION: There is provided a coating composition containing: a first thickener that is a metal crosslinking thickener, preferably selected from the group consisting of a carboxyvinyl polymer and sodium alginate; a polyvalent metal compound; and at least one second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate (provided that the second thickener is not sodium alginate when the first thickener is sodium alginate).SELECTED DRAWING: None

Description

The present invention relates to an easy-to-take oral preparation with improved dosing and / or a coating composition used for an easy-to-take preparation with improved dissolution.

Currently, pharmaceuticals account for a large percentage of oral preparations, and solid preparations are the mainstream, but there are many preparations with large doses, and these preparations are larger when single-unit tablets are used. In the case of powders or granules, the density is low, resulting in a bulky preparation, which is often difficult for children and elderly people with low swallowing function.
In order to improve the dosage of tablets, the technique of intraoral quick disintegrating tablets has been developed. However, since the content of the active ingredient in the whole tablet is small, it is not suitable for a preparation having a high content of the active ingredient. When the intraoral quick disintegrating tablet is enlarged, the foreign body sensation in the oral cavity after the disintegration is increased. Furthermore, when the main drug has an unpleasant taste such as a bitter taste, there are many problems such as difficulty in masking.
In addition, preparations such as liquids and jellies have been proposed as dosage forms with good dosing properties, but even in these dosage forms, masking of the taste is difficult when the content of the active ingredient is high, and further in water It has the problem of ensuring stability.
An example of a high-dose formulation is a cholesterol-lowering agent whose active ingredient is colestimide, an anion exchange resin, and a multi-unit formulation (mini tablet packaging) is used to make the formulation compact and easy to take. Developed and sold. Patent No. 38835
No. 05 (Patent Document 1) disintegrates minitablets in the oral cavity by coating with ethylcellulose after coating with water-soluble polymer cellulose to improve the dosage of colestimide multi-unit preparation (minitablet). There is a description that it is possible to prevent agglomeration and deterioration of the dosage. However, there is no description regarding a technique for improving the slipping of the tablet to facilitate swallowing.

In recent years, as a technique for facilitating swallowing of a solid preparation, a technique using a gelling agent with good mucosal sliding has been developed. For example, in JP 2000-516222 (Patent Document 2), in the granules, pellets and mini-tablets, the inner layer is coated with a high-viscosity gelling agent, and the outer layer is coated with a low-viscosity gelling agent. And formulations with improved ease of swallowing are described. However, in the method disclosed herein, it takes a long time to form a gel, and the formed gel has a drawback that adhesion to the mucous membrane becomes high.
Japanese Patent Application Laid-Open No. 2002-275054 (Patent Document 3) describes an easy-to-swallow tablet coated with a coating liquid containing 40 parts or more of sugar alcohol when xanthan gum is used as a gelling agent and the coating solid content composition is 100 parts. There is. This coating does not feel slimy or sticky when contained in the oral cavity, and the mucous membrane is slippery. However, xanthan gum alone has a gel formed in the oral cavity that is too soft, and bitterness masking is insufficient. Further improvement is also required in terms of slipperiness.
Japanese Patent No. 4267926 (Patent Document 4) discloses a film agent that gels.
This film preparation is a sheet-form preparation in which the drug layer is sandwiched between carboxyvinyl polymer layers cross-linked with a polyvalent metal salt. It quickly gels in the oral cavity, and is less likely to be caught in the throat and masks bitterness. It is described. However, there is no disclosure regarding coating of tablets and granules. Since the carboxyvinyl polymer of the present technology is used in the production process as a very viscous solution crosslinked with polyvalent metal ions, it is considered difficult to spray-coat tablets and granules (see Reference Example 1 described later). ). Therefore, a film agent that can be manufactured by the present technology requires a special process and apparatus of application, and tends to increase the manufacturing cost as compared with coating of tablets and granules. Furthermore, as described in Reference Example 2 described later, the coated mini-tablet produced by improving the present technology so as to enable spray coating could not obtain practically satisfactory swallowing ease.
On the other hand, when coating is performed with a gelling agent, there is a concern that when a gel is formed in the digestive tract, diffusion of the drug is suppressed and elution delay occurs. JP-A-11-60472 (Patent Document 5)
) Discloses that in a swallow-coated tablet coated with methylcellulose, dissolution delay can be prevented by adding a saccharide. However, with this coated tablet, it is not possible to expect a feeling of unity in the oral cavity when minitablets are formed.
Thus, it is a big subject to prevent the drug elution delay in the preparation coated with the gelling agent.

Patent No. 3883505 Special table 2000-516222 JP 2002-275054 A Japanese Patent No. 4267926 Japanese Patent Laid-Open No. 11-60472

As described above, it is desired to provide a coating preparation that has a masking effect of unpleasant taste such as bitterness, good swallowability, and is easy to manufacture in preparations for oral administration, particularly tablets having a high dose. It is rare. It is also desired to provide a coating preparation with improved dissolution. It is an object to provide a coating preparation having any one or more, preferably all of these properties, and a coating composition for producing the same.

In view of the above problems, the present inventors have conducted intensive studies for the purpose of improving the dosage of oral preparations. As a result, a first thickener such as carboxyvinyl polymer as a thickener and a second thickener such as xanthan gum. By coating a solid composition for oral use such as tablets with a coating composition to which a small amount of a polyvalent metal compound is added as a viscosity modifier, the unpleasant taste is masked and the mucous membrane is more slippery. Therefore, it has been found that it becomes easy to swallow and manufacture becomes easy. In addition, the present inventors have found that an unpleasant taste masking effect is further improved by adding sucralose to the coating composition. Furthermore, the present inventors added hydroxypropylmethylcellulose (hereinafter sometimes referred to as HPMC), sugar or sugar alcohol having specific properties to the coating composition, so that the film disintegrated rapidly after swallowing and delayed dissolution. The present inventors have found that it can be prevented and completed the present invention.

That is, the first aspect of the present invention is the following coating composition.
[1-1] A first thickener which is a metal crosslinking thickener, preferably a first thickener selected from the group consisting of carboxyvinyl polymer and sodium alginate;
A polyvalent metal compound; and
At least one or more second thickeners selected from the group consisting of xanthan gum, guar gum and sodium alginate (provided that when the first thickener is sodium alginate, the second thickener is sodium alginate) Coating composition comprising).
[1-1a] A coating composition comprising a carboxyvinyl polymer, a polyvalent metal compound, and xanthan gum.
[1-2] The coating composition according to [1-1], wherein the first thickener is a carboxyvinyl polymer or sodium alginate that is not substantially crosslinked with a polyvalent metal ion.
[1-2a] The coating composition according to [1-1a], wherein the carboxyvinyl polymer is not substantially crosslinked.
[1-3] The above [1-1] further comprising a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more.
, [1-2], [1-1a], and [1-2a].
[1-4] The coating composition according to any one of [1-1] to [1-3], [1-1a], and [1-2a], further including HPMC.
[1-5] The content of the first thickener is 3 to 15% by mass or 3 to 20% by mass (% by mass in all components excluding the solvent, the same shall apply hereinafter), and the second thickener The content of is 40 to 40% by mass, the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass. 1-4] The composition for coating.
[1-5a] The content of carboxyvinyl polymer is 3 to 15% by mass or 3 to 20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), and the content of xanthan gum is 10
In the above [1-4], the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass. The coating composition as described.
[1-6] The above [1-1] to [1-5], wherein the content of the polyvalent metal compound is 2 to 15% by mass with respect to the content of the first thickener. The coating composition according to any one of the above.
[1-6a] The content of the polyvalent metal compound is 2 to 2 with respect to the content of the carboxyvinyl polymer.
Said [1-1a], [1-2a], [1-3], [1
-4] and [1-5a] The coating composition according to any one of [1-5a].
[1-7] [1-1] to [1-6], which contains alcohol as a solvent, [1-6]
The coating composition according to any one of 1-1a], [1-2a], [1-5a], and [1-6a].
[1-8] The above [1-1] to [1-7], [1-1a], which further contain sucralose,
The coating composition according to any one of [1-2a], [1-5a], and [1-6a].
[1-9] The content of the first thickener is 3 to 20% by mass (% by mass in all components excluding the solvent, the same shall apply hereinafter), and the content of the second thickener is 10 to 10%. 40% by mass, sucralose content is 0.01-5% by mass, HPMC content is 5-35% by mass, and the sugar or sugar alcohol content is 10-50% by mass. % [1-8]
] The coating composition as described in.
[1-9a] The content of carboxyvinyl polymer is 3 to 20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), and the content of xanthan gum is 10 to 40% by mass,
The sucralose content is 0.01 to 5% by mass, the HPMC content is 5 to 35% by mass, and the sugar or sugar alcohol content is 10 to 50% by mass. The coating composition as described in [1-8] above.
The oral composition coated with the coating composition according to the first aspect of the present invention comprises:
Good slipperiness and good swallowability without adhesion to mucous membranes. Or sufficient unpleasant taste masking effect is acquired. Preferably, both effects are combined. Furthermore, in the coating composition of a preferred embodiment, the drug dissolution property is also improved. In another preferred embodiment of the coating composition, the drug core can be easily spray-coated and can be easily dried.

The second aspect of the present invention is the following oral composition.
[2-1] a drug nucleus containing an active ingredient;
In the drug nucleus,
A first thickener that is a metal crosslinking thickener, preferably a first thickener selected from the group consisting of carboxyvinyl polymer and sodium alginate;
A polyvalent metal compound and at least one or more second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate (provided that the second thickener is when the first thickener is sodium alginate) An oral composition having a coating comprising a thickener is not sodium alginate).
[2-1a] An oral composition having a drug core containing an active ingredient and a coating containing a carboxyvinyl polymer, a polyvalent metal compound and xanthan gum on the drug core.
[2-2] The oral composition according to [2-1], wherein the first thickener is a carboxyvinyl polymer or sodium alginate that is not substantially crosslinked with a polyvalent metal ion.
[2-2a] The oral composition according to [2-1a], wherein the carboxyvinyl polymer is not substantially crosslinked.
[2-3] Any of the above [2-1], [2-2], [2-1a], and [2-2a], wherein the coating further contains a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more. Or one
Oral composition as described in claim | item.
[2-4] [2-1] to [2-3], [2-3], wherein the coating further contains HPMC
The oral composition according to any one of 2-1a] and [2-2a].
[2-5] The content of the first thickener is 3 to 15% by mass or 3 to 20% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), Content is 10-4
The content of HPMC is 0 to 35% by mass, the content of the sugar or sugar alcohol is 10 to 50% by mass, and described in [2-4] Oral composition.
[2-5a] The content of carboxyvinyl polymer is 3 to 15% by mass or 3 to 20% by mass (% by mass relative to all components in the coating, the same shall apply hereinafter), and the content of xanthan gum is 10 to 40% by mass The content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass, as described in [2-4] Composition.
[2-6] In the above [2-1] to [2-5], the content of the polyvalent metal compound is 2 to 15% by mass with respect to the content of the first thickener. The composition for oral administration according to any one of the above.
[2-6a] The content of the polyvalent metal compound is 2 to 2 with respect to the content of the carboxyvinyl polymer.
[2-1a], [2-2a], [2-3], [2
-4] and [2-5a].
[2-7] The above [2-1], wherein the drug nucleus is a tablet nucleus containing an active ingredient
The composition for oral administration according to any one of to [2-6], [2-1a], [2-2a], [2-5a], and [2-6a].
[2-8] The second thickener is at least one or more thickeners selected from the group consisting of xanthan gum, guar gum, and sodium alginate substantially not crosslinked with a polyvalent metal ion. The composition for oral administration according to any one of [2-1] to [2-7].
[2-9] Further comprising a seal coating between the drug nucleus and the coating,
2-1] to [2-8], [2-1a], [2-2a], [2-5a], and [2-6a]
] The composition for oral administration of any one of.
[2-10] The above [2-1] to [2-], wherein the coating further contains sucralose.
9], [2-1a], [2-2a], [2-5a], and the composition for oral use according to any one of [2-6a].
[2-11] The content of the first thickener is 3 to 20% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), and the content of the second thickener is 10 to 40%. The content of sucralose is 0.01 to 5% by mass, the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass. The composition for oral administration according to [2-10] above,
[2-11a] The content of carboxyvinyl polymer is 3 to 20% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), the content of xanthan gum is 10 to 40% by mass, The content is 0.01 to 5% by mass, the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass Oral composition as described in [2-10].
[2-12] The oral composition according to any one of [2-9] to [2-11] and [2-11a], further having a middle coating between the seal coating and the coating.
The oral composition of the second embodiment of the present invention has good swallowability without slipperiness and adhesion to mucous membranes. Or an unpleasant taste masking effect is acquired. Preferably, both effects are combined. In a further preferred embodiment of the oral composition, the drug dissolution is also improved.

The third aspect of the present invention is the following oral composition.
[3-1] A first thickener selected from the group consisting of a first thickener, preferably a carboxyvinyl polymer or sodium alginate, which is a metal crosslinking thickener in an alcohol solution in which a polyvalent metal compound is dissolved. And at least one second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate (provided that the first thickener is sodium alginate, the second thickener Is not sodium alginate)
An oral composition obtained by spray coating a drug core containing an active ingredient on a drug nucleus containing an active ingredient.
[3-1a] An oral composition obtained by spray coating a drug core containing an active ingredient with a liquid in which a carboxyvinyl polymer and xanthan gum are dispersed in an alcohol solution in which a polyvalent metal compound is dissolved.
[3-2] The oral composition according to [3-1], wherein the first thickener is a carboxyvinyl polymer or sodium alginate that is not substantially crosslinked with a polyvalent metal ion.
[3-2a] The oral composition according to [3-1a], wherein the carboxyvinyl polymer is not substantially crosslinked.
[3-3] Sugar or sugar alcohol having a solubility of 30 or more at 20 ° C. is further dispersed in the liquid to be spray-coated, [3-1], [3-2], [3
The composition for oral administration according to any one of [-1a] and [3-2a].
[3-4] The above [3-1] to [3], wherein HPMC is further contained in the liquid to be spray coated.
The composition for oral administration according to any one of [3-3], [3-1a], and [3-2a].
[3-5] The content of the first thickener in the liquid to be spray-coated is 3 to 15% by mass or 3 to 20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), The content of the thickener 2 is 10 to 40% by mass, the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass. [3-4]
] The composition for oral administration as described in.
[3-5a] The content of carboxyvinyl polymer in the liquid to be spray-coated is 3-1
5% by mass or 3-20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter),
The xanthan gum content is 10 to 40% by mass, the HPMC content is 5 to 35% by mass, and the sugar or sugar alcohol content is 10 to 50% by mass. Oral composition as described in [3-4].
[3-6] The above [3-1] to [3-5], wherein the content of the polyvalent metal compound is 2 to 15% by mass relative to the content of the first thickener. The composition for oral administration according to any one of the above.
[3-6a] The content of the polyvalent metal compound is 2 to 2 with respect to the content of the carboxyvinyl polymer.
15% by mass, [3-1a], [3-2a], [3-3], [3
-4] and [3-5a].
[3-7] The above [3-1], wherein the drug nucleus is a tablet nucleus containing an active ingredient
The composition for oral administration according to any one of to [3-6], [3-1a], [3-2a], [3-5a], and [3-6a].
[3-8] The second thickener is at least one thickener selected from the group consisting of xanthan gum, guar gum, and sodium alginate substantially not cross-linked with polyvalent metal ions. The composition for oral administration according to any one of [3-1] to [3-7].
[3-9] [3-1] to [3-8], [3-1a], [3-2a], [3-8], [3-8], [3-8], [3-8] 3
−5a] and [3-6a] The oral composition according to any one of [3-6a].
[3-10] The liquid to be spray-coated further contains sucralose, [3-1
]-[3-9], [3-1a], [3-2a], [3-5a], and the composition for oral use of any one of [3-6a].
[3-11] The content of the first thickener in the liquid to be spray-coated is 3 to 20% by mass (
% By mass in all components excluding solvent, the same shall apply hereinafter), and the content of the second thickener is 10 to 40
The content of sucralose is 0.01 to 5% by mass, the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass. The composition for oral administration according to [3-10] above,
[3-11a] The content of carboxyvinyl polymer in the liquid to be spray-coated is 3
~ 20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), the xanthan gum content is 10-40% by mass, and the sucralose content is 0.01-5% by mass. The HPMC content is 5 to 35% by mass, and the sugar or sugar alcohol content is 10%.
It is -50 mass%, The composition for oral administration as described in said [3-10] characterized by the above-mentioned.
[3-12] The oral cavity according to any one of [3-9] to [3-11] and [3-11a], wherein the seal coat drug nucleus further has a middle coating on the seal coating Composition.
The oral composition of the third aspect of the present invention has good swallowability and good slipperiness and no adhesion to mucous membranes. Or sufficient unpleasant taste masking effect is acquired. Preferably, both effects are combined. In a further preferred embodiment of the oral composition, the drug dissolution is also improved.

The fourth aspect of the present invention is the following method for producing an oral composition.
[4-1] A method for producing an oral composition comprising a first thickener, preferably a carboxyvinyl polymer and sodium alginate, which is a metal crosslinking thickener in an alcohol solution in which a polyvalent metal compound is dissolved. A first thickener selected from the group consisting of xanthan gum,
At least one or more second thickener selected from the group consisting of guar gum and sodium alginate (provided that when the first thickener is sodium alginate, the second thickener is not sodium alginate) ) Is dispersed on a drug core containing an active ingredient, and a method for producing an oral composition is provided.
[4-1a] A method for producing an oral composition, wherein a drug core containing an active ingredient is spray coated with a solution in which a carboxyvinyl polymer and xanthan gum are dispersed in an alcohol solution in which a polyvalent metal compound is dissolved. A method for producing an oral composition characterized by the above.
[4-2] The method for producing an oral composition according to the above [4-1], wherein the first thickener is a carboxyvinyl polymer or sodium alginate which is not substantially crosslinked with a polyvalent metal ion.
[4-2a] The method for producing an oral composition according to [4-1a], wherein the carboxyvinyl polymer is not substantially crosslinked.
[4-3] The above [4-1], [4-2], [4], wherein a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more is further dispersed in the liquid to be spray-coated.
The method for producing an oral composition according to any one of [-1a] and [4-2a].
[4-4] The above-mentioned [4-1] to [4], wherein the liquid to be spray-coated further contains HPMC
4-3], [4-1a], and the method for producing an oral composition according to any one of [4-2a].
[4-5] The content of the first thickener in the liquid to be spray-coated is 3 to 15% by mass or 3 to 20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), The content of the thickener 2 is 10 to 40% by mass, the content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass. [4-4]
] The manufacturing method of the composition for oral administration of description.
[4-5a] The content of carboxyvinyl polymer in the liquid to be spray-coated is 3 to 1
5% by mass or 3-20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter),
The xanthan gum content is 10 to 40% by mass, the HPMC content is 5 to 35% by mass, and the sugar or sugar alcohol content is 10 to 50% by mass. The method for producing an oral composition according to [4-4].
[4-6] In the above [4-1] to [4-5], the content of the polyvalent metal compound is 2 to 15% by mass with respect to the content of the first thickener. The manufacturing method of the composition for oral administration of any one.
[4-6a] The content of the polyvalent metal compound is 2 to 2 with respect to the content of the carboxyvinyl polymer.
[4-1a], [4-2a], [4-3], [4], which is 15% by mass.
-4] and the method for producing an oral composition according to any one of [4-5a].
[4-7] The above [4-1], wherein the drug nucleus is a tablet nucleus containing an active ingredient.
~ [4-6], [4-1a], [4-2a], [4-5a], and a method for producing an oral composition according to any one of [4-6a].
[4-8] The second thickener is at least one thickener selected from the group consisting of xanthan gum, guar gum, and sodium alginate substantially not cross-linked with a polyvalent metal ion. The method for producing an oral composition according to any one of [4-1] to [4-7].
[4-9] The above [4-1] to [4-8], [4-1a], [4-2a], [4-2], wherein the drug nucleus to which the spray coating is applied is a seal coat drug nucleus having a seal coating 4
−5a] and [4-6a] The method for producing an oral composition according to any one of [4-6a].
[4-10] The liquid to be spray-coated further contains sucralose, [4-1
] To [4-9], [4-1a], [4-2a], [4-5a] and [4-6a] The method for producing an oral composition according to any one of [4-6a].
[4-11] The content of the first thickener in the liquid to be spray-coated is 3 to 20% by mass (% by mass in all components excluding the solvent, the same shall apply hereinafter), and the second thickener. The content of
40% by mass, sucralose content is 0.01-5% by mass, HPMC content is 5-35% by mass, and the sugar or sugar alcohol content is 10-50% by mass. %
The method for producing an oral composition according to [4-10] above, wherein
[4-11a] The content of carboxyvinyl polymer in the liquid to be spray-coated is 3 to 20% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), and the content of xanthan gum is 10 to 40% by mass. The sucralose content is 0.01 to 5% by mass, the HPMC content is 5 to 35% by mass, and the sugar or sugar alcohol content is 1%.
It is 0-50 mass%, The manufacturing method of the composition for oral administration as described in said [4-10] characterized by the above-mentioned.
[4-12] The oral cavity according to any one of [4-9] to [4-11] and [4-11a], wherein the seal coat drug nucleus further has a middle coating on the seal coating A method for producing a composition.
In the method for producing an oral composition according to the fourth aspect of the present invention, the drug core can be easily spray-coated and dried easily. In addition, the oral composition obtained by this production method has good slipperiness and good swallowability without adhesion to mucous membranes. Or sufficient unpleasant taste masking effect is acquired. Preferably, both effects are combined. Furthermore, in the oral composition obtained by the production method of a preferred embodiment, the drug dissolution property is also improved.

The fifth aspect of the present invention is the following coating composition.
[5-1] A coating composition comprising a thickener that gels upon contact with moisture, a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more, and HPMC.
[5-2] The coating composition according to [5-1], wherein the thickener is at least one selected from the group consisting of xanthan gum, guar gum, and sodium alginate.
[5-2a] The coating composition according to [5-1], wherein the thickener includes xanthan gum.
[5-3] The coating composition according to [5-1], wherein the thickener is selected from the group consisting of a carboxyvinyl polymer and sodium alginate.
[5-3a] The coating composition according to [5-1], wherein the thickener includes a carboxyvinyl polymer.
[5-4] One type selected from the group consisting of a carboxyvinyl polymer and sodium alginate as the thickener, and at least one type selected from the group consisting of xanthan gum, guar gum and sodium alginate (however, a combination of the same substances) Including the above-mentioned [5-
[1] The coating composition according to [1].
[5-4a] The above-mentioned [5-1, wherein the thickener contains a carboxyvinyl polymer and xanthan gum.
] The coating composition as described in.
[5-5] The coating composition as described in [5-3], [5-4], [5-3a] or [5-4a], further containing a polyvalent metal compound.
[5-6] The above-mentioned [5-1] to [5-5] and [5-2a] to which the mixing ratio of HPMC and the sugar or sugar alcohol is 1: 1 to 1: 4 [5-4a] The coating composition according to any one of [5-4a].
[5-7] The HPMC content is 5 to 35% by mass (% by mass in all components excluding the solvent, the same shall apply hereinafter), and the sugar or sugar alcohol content is 10 to 50% by mass. The content of the carboxyvinyl polymer is 3 to 15% by mass or 3 to 20% by mass, and the content of at least one selected from the group consisting of the xanthan gum, guar gum and sodium alginate is 10 to 40% by mass [5-4] to [5-6]
] The coating composition of any one of these.
[5-7a] The content of HPMC is 5 to 35% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 50% by mass. The content of carboxyvinyl polymer is 3 to 15% by mass or 3 to 20% by mass, and the content of xanthan gum is 10 to 40% by mass, [5-4a], [5-
5], and the composition for coating of any one of [5-6].
[5-8] The above [5-1] to [5-7], comprising alcohol as a solvent.
, [5-2a] to [5-4a], and [5-7a].
[5-9] [5-1] to [5-8], [5-2a] to [5-4a], wherein the sugar or sugar alcohol is selected from the group consisting of erythritol, reduced maltose starch syrup, and trehalose.
] And the coating composition according to any one of [5-7a].
[5-10] The coating composition according to [5-9], wherein the sugar or sugar alcohol is erythritol.
[5-11] The above [5-1] to [5-10], [5-2a, further comprising sucralose.
]-[5-4a] and the coating composition of any one of [5-7a].
[5-12] The content of HPMC is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 50% by mass. The content of the carboxyvinyl polymer is 3 to 20% by mass, and the content of at least one selected from the group consisting of the xanthan gum, guar gum and sodium alginate is 1
It is 0-40 mass%, Comprising: Content of a sucralose is 0.01-5 mass%, The composition for coating as described in said [5-11] characterized by the above-mentioned.
[5-12a] The content of HPMC is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 50% by mass. The carboxyvinyl polymer content is 3 to 20% by mass, and the xanthan gum content is 1
It is 0-40 mass%, Comprising: Content of a sucralose is 0.01-5 mass%, The composition for coating as described in said [5-11] characterized by the above-mentioned.
The oral composition coated with the coating composition of the fifth aspect of the present invention exhibits approximately the same drug dissolution as an uncoated oral composition. Moreover, in the coating composition of a preferable aspect, it is easy to slip and has good swallowability without adhesion to mucous membranes. Or an unpleasant taste masking effect is acquired. Preferably, both effects are combined. In another preferred embodiment of the coating composition, the drug core can be easily spray-coated and can be easily dried.

The sixth aspect of the present invention is the following oral composition.
[6-1] A drug nucleus containing an active ingredient and a thickener that gels by contact with moisture, 2
An oral composition having a coating comprising a sugar or sugar alcohol having a solubility at 0 ° C. of 30 or more and HPMC.
[6-2] The oral composition according to [6-1], wherein the thickener is at least one selected from the group consisting of xanthan gum, guar gum, and sodium alginate.
[6-2a] The oral composition according to [6-1], wherein the thickener includes xanthan gum.
[6-3] The oral composition according to [6-1], wherein the thickener is selected from the group consisting of carboxyvinyl polymer and sodium alginate.
[6-3a] The oral composition according to [6-1], wherein the thickener includes a carboxyvinyl polymer.
[6-4] The thickener is at least one selected from the group consisting of carboxyvinyl polymer and sodium alginate, and at least one selected from the group consisting of xanthan gum, guar gum and sodium alginate (however, a combination of the same substances) [6]
-1].
[6-4a] The above [6-1], wherein the thickener contains a carboxyvinyl polymer and xanthan gum.
] The composition for oral administration as described in.
[6-5] The above [6-3], [6-4] further containing a polyvalent metal compound in the coating
], [6-3a], and the composition for oral use of any one of [6-4a].
[6-6] The above-mentioned [6-1] to [6-5] and [6-2a], wherein the mixing ratio of HPMC to the sugar or sugar alcohol is 1: 1 to 1: 4 Any one of [6-4a]
Oral composition as described in claim | item.
[6-7] The content of HPMC is 5 to 35% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 50% by mass, The content of one kind selected from the group consisting of carboxyvinyl polymer and sodium alginate is 3 to 15% by mass or 3 to 20% by mass, and at least one selected from the group consisting of the xanthan gum, guar gum and sodium alginate The oral composition according to any one of [6-4] to [6-6] above, wherein the content of seeds or more is 10 to 40% by mass.
[6-7a] HPMC content is 5 to 35% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), and the sugar or sugar alcohol content is 10 to 50% by mass, [6-4a], wherein the content of carboxyvinyl polymer is 3 to 15% by mass or 3 to 20% by mass, and the content of xanthan gum is 10 to 40% by mass.
Oral composition of any one of [6-5] and [6-6].
[6-8] The above [6], wherein the drug nucleus is a seal coat drug nucleus having a seal coating
-1] to [6-7], [6-2a] to [6-4a], and [6-7a].
[6-9] The above [6-1] to [6-8], [6-2a] to [6-4a], wherein the sugar or sugar alcohol is selected from the group consisting of erythritol, reduced maltose starch syrup and trehalose.
] And the composition for oral administration of any one of [6-7a].
[6-10] The composition for oral administration according to the above [6-9], wherein the sugar or sugar alcohol is erythritol.
[6-11] The above [6-1] to [6-], wherein the coating further contains sucralose.
[10], [6-2a] to [6-4a], and [6-7a].
[6-12] The content of HPMC is 5 to 35% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 50% by mass, 1 selected from the group consisting of carboxyvinyl polymer and sodium alginate
The content of the seed is 3 to 20% by mass, and the content of at least one selected from the group consisting of xanthan gum, guar gum and sodium alginate is 10 to 40% by mass, and the content of sucralose is 0.01 to 5% by mass [6-
11].
[6-12a] HPMC content is 5 to 35% by mass (% by mass relative to all components in the coating, the same shall apply hereinafter), and the sugar or sugar alcohol content is 10 to 50% by mass, The carboxyvinyl polymer content is 3 to 20% by mass, the xanthan gum content is 10 to 40% by mass, and the sucralose content is 0.01 to 5% by mass. The composition for oral administration according to [6-11].
[6-13] The oral cavity according to any one of [6-8] to [6-12] and [6-12a], wherein the seal coat drug nucleus further has a middle coating on the seal coating Composition.
Although the oral composition of the sixth aspect of the present invention is coated with a thickener, it exhibits approximately the same drug dissolution as an uncoated oral composition. Moreover, in the composition for oral use of a preferable aspect, it is easy to slip and has good swallowability without adhering to the mucous membrane. Or sufficient unpleasant taste masking effect is acquired. Preferably, both effects are combined.

The seventh aspect of the present invention is the following oral composition.
[7-1] A thickener that gels by contact with moisture in an alcohol solution, a solution in which a sugar having a solubility of 20 or more at 20 ° C. or a sugar alcohol and HPMC are dispersed in a drug nucleus containing an active ingredient An oral composition obtained by spray coating.
[7-2] The oral composition according to [7-1], wherein the thickener is at least one selected from the group consisting of xanthan gum, guar gum, and sodium alginate.
[7-2a] The oral composition according to [7-1], wherein the thickener includes xanthan gum.
[7-3] The oral composition according to [7-1], wherein the thickener is selected from the group consisting of carboxyvinyl polymer and sodium alginate.
[7-3a] The oral composition according to [7-1], wherein the thickener includes a carboxyvinyl polymer.
[7-4] The thickener is at least one selected from the group consisting of carboxyvinyl polymer and sodium alginate, and at least one selected from the group consisting of xanthan gum, guar gum and sodium alginate (however, a combination of the same substances) [7-
Oral composition as described in 1].
[7-4a] The above [7-1, wherein the thickener contains a carboxyvinyl polymer and xanthan gum.
] The composition for oral administration as described in.
[7-5] The above-mentioned [7-3], wherein the liquid for spray coating further contains a polyvalent metal compound.
, [7-4], [7-3a] or [7-4a].
[7-6] The above-mentioned [7-1] to [7-5], wherein the mixing ratio of HPMC of the liquid to be spray-coated and the sugar or sugar alcohol is 1: 1 to 1: 4, and [7-6] 7-2a
] The composition for oral administration of any one of [7-4a].
[7-7] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 10%.
50% by mass and the content of carboxyvinyl polymer is 3 to 15% by mass or 3 to 3% by mass
[7-4] to [7], wherein the content is 20% by mass, and the content of at least one selected from the group consisting of xanthan gum, guar gum and sodium alginate is 10 to 40% by mass. The composition for oral administration according to any one of [6].
[7-7a] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10%.
To 50% by mass, and the content of carboxyvinyl polymer is 3 to 15% by mass or 3%.
Any one of [7-4a], [7-5], and [7-6] above, wherein the content of xanthan gum is 10 to 40% by mass. The oral composition described.
[7-8] The above [7-1] to [7-7], [7-2a] to [7-4a], wherein the drug core to which the spray coating is applied is a seal coat drug nucleus having a seal coating, and The composition for oral administration according to any one of [7-7a].
[7-9] [7-1] to [7-8], [7-2a] to [7-4a] wherein the sugar or sugar alcohol is selected from the group consisting of erythritol, reduced maltose starch syrup and trehalose.
], And the composition for oral administration of any one of [7-7a].
[7-10] The composition for oral administration according to the above [7-9], wherein the sugar or sugar alcohol is erythritol.
[7-11] The liquid to be spray-coated further contains sucralose, [7-1
] To [7-10], [7-2a] to [7-4a], and [7-7a].
[7-12] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10%.
-50% by mass, the content of carboxyvinyl polymer is 3-20% by mass,
The content of at least one selected from the group consisting of the xanthan gum, guar gum and sodium alginate is 10 to 40% by mass, and the content of sucralose is 0.0
It is 1-5 mass%, The composition for oral administration as described in said [7-11] characterized by the above-mentioned.
[7-12a] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 1
0-50 mass%, carboxyvinyl polymer content 3-20 mass%, xanthan gum content 10-40 mass%, sucralose content 0.0
It is 1-5 mass%, The composition for oral administration as described in said [7-11] characterized by the above-mentioned.
[7-13] The oral cavity according to any one of [7-8] to [7-12] and [7-12a], wherein the seal coat drug nucleus further has a middle coating on the seal coating. Composition.
The oral composition of the seventh aspect of the present invention is obtained by spray-coating an alcohol solution on the drug core and drying, and is easy to manufacture. In addition, although it is coated with a thickener, it exhibits almost the same drug dissolution as an uncoated oral composition. Moreover, in the composition for oral use of a preferable aspect, it is easy to slip and has good swallowability without adhering to the mucous membrane. Or sufficient unpleasant taste masking effect is acquired. Preferably, both effects are combined.

The eighth aspect of the present invention is the following method for producing an oral composition.
[8-1] A method for producing an oral composition, a thickener that gels by contacting moisture in an alcohol solution in which a polyvalent metal compound is dissolved, a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more And a liquid in which HPMC is dispersed is spray-coated on a drug core containing an active ingredient.
[8-2] The method for producing an oral composition according to [8-1], wherein the thickener is at least one selected from the group consisting of xanthan gum, guar gum, and sodium alginate.
[8-2a] The method for producing an oral composition according to [8-1], wherein the thickener contains xanthan gum.
[8-3] The method for producing an oral composition according to [8-1], wherein the thickener is selected from the group consisting of a carboxyvinyl polymer and sodium alginate.
[8-3a] The method for producing an oral composition according to [8-1], wherein the thickener contains a carboxyvinyl polymer.
[8-4] The thickener is at least one selected from the group consisting of carboxyvinyl polymer and sodium alginate, and at least one selected from the group consisting of xanthan gum, guar gum and sodium alginate (however, a combination of the same substances) [8-
[1] A method for producing an oral composition according to [1].
[8-4a] The above [8-1, wherein the thickener contains a carboxyvinyl polymer and xanthan gum.
] The manufacturing method of the composition for oral administration of description.
[8-5] The above-mentioned [8-1] to [8-4], wherein the mixing ratio of HPMC of the liquid to be spray-coated and the sugar or sugar alcohol is 1: 1 to 1: 4, and [8-5] 8-2a
] The manufacturing method of the composition for oral administration of any one of [8-4a].
[8-6] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10 to 10%.
50% by mass, and one content selected from the group consisting of carboxyvinyl polymer and sodium alginate is 3 to 15% by mass or 3 to 20% by mass, and the xanthan gum, guar gum and sodium alginate The above [8-4] or [8], wherein the content of at least one selected from the group is 10 to 40% by mass
8-5]. The method for producing an oral composition according to 8-5].
[8-6a] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10%.
To 50% by mass, and the content of carboxyvinyl polymer is 3 to 15% by mass or 3%.
The method for producing an oral composition according to [8-4a] or [8-5] above, wherein the content of xanthan gum is 10 to 40% by mass.
[8-7] The above [8-1], wherein the drug core is a tablet core containing an active ingredient.
~ [8-6], [8-2a] to [8-4a], and the method for producing an oral composition according to any one of [8-6a].
[8-8] The above [8-1] to [8-7], [8-2a] to [8-4a], wherein the drug core to which the spray coating is applied is a seal coat drug nucleus having a seal coating, and The method for producing an oral composition according to any one of [8-6a].
[8-9] The above [8-1] to [8-8], [8-2a] to [8-4a], wherein the sugar or sugar alcohol is selected from the group consisting of erythritol, reduced maltose starch syrup and trehalose.
] And the manufacturing method of the composition for oral use of any one of [8-6a].
[8-10] The method for producing an oral composition according to [8-9], wherein the sugar or sugar alcohol is erythritol.
[8-11] The liquid to be spray-coated further contains sucralose [8-1]
] To [8-10], [8-2a] to [8-4a], and the method for producing an oral composition according to any one of [8-6a].
[8-12] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components except the solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 10%.
-50% by mass, the content of carboxyvinyl polymer is 3-20% by mass,
The content of at least one selected from the group consisting of the xanthan gum, guar gum and sodium alginate is 10 to 40% by mass, and the content of sucralose is 0.0
It is 1-5 mass%, The manufacturing method of the composition for oral administration as described in said [8-11] characterized by the above-mentioned.
[8-12a] The content of HPMC in the liquid to be spray-coated is 5 to 35% by mass (% by mass in all components excluding solvent, the same shall apply hereinafter), and the content of the sugar or sugar alcohol is 1
0-50 mass%, carboxyvinyl polymer content 3-20 mass%, xanthan gum content 10-40 mass%, sucralose content 0.0
It is 1-5 mass%, The manufacturing method of the composition for oral administration as described in said [8-11] characterized by the above-mentioned.
[8-13] The oral cavity according to any one of [8-8] to [8-12], and [8-12a], wherein the seal coat drug nucleus further has a middle coating on the seal coating. A method for producing a composition.
In the method for producing an oral composition according to the eighth aspect of the present invention, the drug core can be easily spray-coated and dried easily. In addition, the oral composition obtained by this production method shows the dissolution property of the drug almost equivalent to that of the uncoated oral composition, although it is coated with the thickener. Moreover, the coating composition obtained by the production method of the preferred embodiment has good slipperiness and good swallowability without adhesion to mucous membranes. Or sufficient unpleasant taste masking effect is acquired. Preferably, both effects are combined.

The ninth aspect of the present invention is the following oral composition.
[9-1] a drug nucleus containing an active ingredient;
In the drug nucleus,
A gel-like material selected from the group consisting of a carboxyvinyl polymer crosslinked by polyvalent metal ions and sodium alginate crosslinked by polyvalent metal ions when water is present, and at least selected from the group consisting of xanthan gum and guar gum An oral composition having a coating comprising one or more thickeners.
[9-2] The oral composition according to [9-1], wherein the coating further contains a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more.
[9-3] The above [9-1] or [9-2], wherein the coating further contains HPMC.
Orally.
[9-4] The content of the gel substance is 3 to 15% by mass or 3 to 20% by mass (mass% with respect to all components in the coating, the same shall apply hereinafter), and the content of the thickener is 10 to 40%. mass%
The content of HPMC is 5 to 35% by mass, and the content of the sugar or sugar alcohol is 10 to 50% by mass, as described in [9-3] above Composition.
[9-5] The above [9-1] to [9-, wherein the coating further contains sucralose.
4] The oral composition according to any one of [4].
[9-6] The content of the gel-like substance is 3 to 20% by mass (% by mass with respect to all components in the coating, the same shall apply hereinafter), and the content of the thickener is 10 to 40% by mass, The HPMC content is 5 to 35% by mass, the sugar or sugar alcohol content is 10 to 50% by mass, and the sucralose content is 0.01 to 5% by mass. [9-
Oral composition as described in 5].
[9-7] The oral composition according to any one of [9-1] to [9-6], further comprising a seal coating between the drug core and the coating.
[9-8] The oral composition according to [9-7], further having a middle coating between the seal coating and the coating.
The oral composition of the ninth aspect of the present invention is equivalent to the oral composition of the second aspect of the present invention produced by moisture such as saliva in the oral cavity. That is, the oral composition of the ninth aspect of the present invention has good swallowability without slipperiness and adhesion to the mucous membrane. Or an unpleasant taste masking effect is acquired. Preferably, both effects are combined. In a further preferred embodiment of the oral composition, the drug dissolution is also improved.

The tenth aspect of the present invention is the following oral composition.
[10-1] Contains levofloxacin hydrate as an active ingredient, and further includes crystalline cellulose, sodium carboxymethyl starch, pregelatinized starch (eg, SWELSTARWB-1)
(Trade name)) and a tablet core (preferably a mini tablet) comprising sodium stearyl fumarate;
A seal coating comprising HPMC (eg, TC-5R (trade name)) and Macrogol 6000 (trade name) on the tablet core;
On the seal coating, a carboxyvinyl polymer (eg, Carbopol 974P (
Trade name)), calcium chloride, xanthan gum, sucralose, HPMC (eg, TC-5)
E (trade name)), a coating comprising erythritol and HPC (eg, HPC-L (trade name)).
[10-2] The content of levofloxacin hydrate in the tablet core (mass in all components excluding the solvent of the tablet core, hereinafter the same) is 69.7% by mass, and the content of crystalline cellulose is 6. 2% by weight, sodium carboxymethyl starch content is 17.7% by weight, pregelatinized starch content is 2.7% by weight, and sodium stearyl fumarate content is 3%.
. 7% by mass,
HPMC content of the seal coating (mass in all components excluding seal coating solvent, hereinafter the same) is 95.2% by mass, and Macrogol 6000 (trade name)
The content of is 4.8% by mass,
The content of carboxyvinyl polymer in the coating (mass in all components excluding coating solvent, hereinafter the same) is 12.7% by mass, and the content of calcium chloride is 0.5%.
The content of xanthan gum is 25.3% by mass, the content of sucralose is 0.8% by mass, the content of HPMC is 15.2% by mass, and the content of erythritol is 35%. 4 mass%, and the content of HPC is 10.1 mass%, [1
0-1] oral composition.
[10-3] The content of levofloxacin hydrate in the tablet core (mass in all components excluding the solvent of the tablet core, hereinafter the same) is 69.7% by mass, and the content of crystalline cellulose is 6. 2% by weight, sodium carboxymethyl starch content is 17.7% by weight, pregelatinized starch content is 2.7% by weight, and sodium stearyl fumarate content is 3%.
. 7% by mass,
HPMC content of the seal coating (mass in all components excluding seal coating solvent, hereinafter the same) is 95.2% by mass, and Macrogol 6000 (trade name)
The content of is 4.8% by mass,
The content of carboxyvinyl polymer in the coating (mass in all components excluding coating solvent, hereinafter the same) is 9.4% by mass, the content of calcium chloride is 0.4% by mass, The content is 26.3% by mass, the sucralose content is 0.9% by mass, the HPMC content is 15.8% by mass, the erythritol content is 36.8% by mass, And the content of HPC is 10.5% by mass, [10
-1] oral composition.
The oral composition of the tenth aspect of the present invention has good swallowability without slipperiness and adhesion to mucous membranes. Or the masking effect with respect to the unpleasant taste which comes from the active ingredient levofloxacin hydrate is acquired. Preferably, both effects are combined. In a further preferred embodiment of the oral composition, the drug dissolution is also improved.

The eleventh aspect of the present invention is the following oral composition.
[11-1] Contains valacyclovir hydrochloride as an active ingredient, and (i) partially pregelatinized starch (eg, PCS (trade name)), sodium carboxymethyl starch, pregelatinized starch (eg, SWELSTAR WB-1 (commodity) Name)), talc and sodium stearyl fumarate, or (ii) partially pregelatinized starch (eg, PCS (trade name)), pregelatinized starch (
An example, SWELSTAR WB-1 (trade name)), a tablet core (preferably a minitablet) comprising talc and sodium stearyl fumarate;
On the tablet core, (iii) pregelatinized starch (eg, SWELSTAR WB-1 (trade name))
And erythritol, or (iv) a seal coating comprising HPMC (eg, TC-5E (trade name)) and erythritol;
On the seal coating, a carboxyvinyl polymer (eg, Carbopol 974P (
Trade name)), calcium chloride, xanthan gum, sucralose, HPMC (eg, TC-5)
E (trade name)), a coating comprising erythritol and HPC (eg, HPC-L (trade name)).
[11-2] The content of valaciclovir hydrochloride in the tablet core (mass in all components excluding the solvent of the tablet core, hereinafter the same) is 75.6% by mass, and the content of partially pregelatinized starch is 4 .6% by mass, the content of sodium carboxymethyl starch is 13.6% by mass, the content of pregelatinized starch is 2.0% by mass, and the content of talc is 2.7% by mass. And the content of sodium stearyl fumarate is 1.4% by mass,
The erythritol content of the seal coating (mass in all components excluding the solvent of the seal coating, hereinafter the same) is 90% by mass, and the pregelatinized starch content is 10%.
Mass%,
The content of carboxyvinyl polymer in the coating (mass in all components excluding coating solvent, hereinafter the same) was 16.7% by mass, and the content of calcium chloride was 0.6.
The content of xanthan gum is 23.4% by mass, the content of sucralose is 0.8% by mass, the content of HPMC is 13.9% by mass, and the content of erythritol is 33%. 4% by mass, and the content of HPC is 11.1% by mass, [1
1-1] Oral composition of description.
[11-3] The content of valacyclovir hydrochloride in the tablet core is 75.6% by mass (mass in all components excluding the solvent of the tablet core, hereinafter the same), and the content of partially pregelatinized starch is 18 .7% by mass
The pregelatinized starch content is 1.5% by weight, the talc content is 2.7% by weight, and the sodium stearyl fumarate content is 1.4% by weight,
The content of HPMC of the seal coating (mass in all components excluding the solvent of the seal coating, hereinafter the same) is 29.4% by mass, and the content of erythritol is 70
. 6% by mass,
Content of carboxyvinyl polymer in the coating (mass in all components excluding solvent,
Hereinafter, the same) is 9.3% by mass, the calcium chloride content is 0.2% by mass, the xanthan gum content is 26.1% by mass, and the sucralose content is 0.9% by mass. [11-1] above, wherein the HPMC content is 15.5% by mass, the erythritol content is 37.3% by mass, and the HPC content is 10.6% by mass. Oral composition.
The oral composition of the eleventh aspect of the present invention has good swallowability with good slipperiness and no adhesion to mucous membranes. Or the masking effect with respect to the unpleasant taste which comes from the active ingredient valaciclovir hydrochloride is acquired. Preferably, both effects are combined. In a further preferred embodiment of the oral composition, the drug dissolution is also improved.

The composition having a preferred coating according to the present invention is a first thickening which is a metal cross-linking thickener by polyvalent metal ions generated from a polyvalent metal compound at the same time that the tablet surface is rapidly gelled by a small amount of water or saliva. Agent, preferably a carboxyvinyl polymer and / or a first thickener such as sodium alginate is cross-linked to increase the viscosity and form a jelly-like relatively hard gel to make it slippery on the mucous membrane Will improve swallowing. Moreover, it can be expected that the gelled coating film exhibits an unpleasant taste masking effect by suppressing drug elution for a short time until swallowing. Furthermore, the composition having a preferred coating of the present invention can be expected to improve the dissolution property such that the film disintegrates rapidly after swallowing and does not affect drug dissolution. The coating composition of the present invention has at least one, preferably all of the above preferred properties. The more preferable coating composition of the present invention can be a formulation with improved dosing property without affecting drug elution when a drug with a large dose is formulated. The particularly preferable coating composition of the present invention further improves the unpleasant taste masking effect.
In addition, with the preferable coating composition of the present invention, a coating preparation can be easily obtained using a normal coating technique.

The present invention will be described in detail below.
The first thickener used in the present invention is a metal crosslinking thickener. A metal cross-linking thickener is cross-linked by a polyvalent metal ion generated from a polyvalent metal compound with a small amount of water and in the absence of water (
In the presence of an alcohol solvent or the like) means a substance that is not crosslinked because a polyvalent metal ion is not generated from a polyvalent metal compound, and is not particularly limited as long as it is a substance that exhibits such properties.
Specific examples include carboxyvinyl polymer, sodium alginate, polyacrylic acid, polymethacrylic acid, pectin, carboxymethyl cellulose, glucomannan, carmellose sodium, and preferably carboxyvinyl polymer and sodium alginate, More preferably, a carboxy vinyl polymer is mentioned. By this cross-linking formation, the viscosity increases and a jelly-like relatively hard gel is formed.
It can be expected to show an unpleasant taste masking effect by suppressing drug elution for a short time until swallowing, making it easier to slip on the mucous membrane when taking and improving swallowability.
The carboxyvinyl polymer used in the present invention is not particularly limited.
Those having a viscosity of 000 to 60000 mPa · s (0.5%, 25 ° C., 20 rpm) can be preferably used. A display viscosity of 4000 to 40,000 mPa · s is more preferable because it hardly causes an elution delay. More specifically, as a carboxyvinyl polymer, a commercially available product,
For example, Carbopol 971P (trade name) (Lublizol AdvancedMat)
erial Inc. , Display viscosity: 6420 mPa · s), Carbopol 974P (trade name)
(Lubrizol Advance Material Inc., display viscosity: 3285
0 mPa · s), Hibiswako 103 (trade name) (Wako Pure Chemical Industries, display viscosity: 15000)
mPa · s), Hibiswako 104 (trade name) (Wako Pure Chemical Industries, display viscosity: 26000)
mPa · s), Hibiswako 105 (trade name) (Wako Pure Chemical Industries, display viscosity: 4000 mP)
a.s) can be used.
The sodium alginate used in the present invention is not particularly limited, but the displayed viscosity is 600.
Those having mPa · s or higher (1% / 1% KCl solution, 25 ° C.) can be preferably used. The display viscosity is preferably 800 to 1600 mPa · s. More specifically, as sodium alginate, commercially available products such as Kimika Argin I-8 (Kimika Company, display viscosity,
800 to 900 mPa · s (1%, 20 ° C.)), Duck Algin (trade name) (Kibun Food Chemifa, display viscosity: 850 mPa · s), and the like can be used.
The first thickener such as carboxyvinyl polymer and sodium alginate has a viscosity increased by being cross-linked by a polyvalent metal ion generated from a polyvalent metal compound described later in the presence of water. It is a metal cross-linking thickener that forms a hard gel. The carboxyvinyl polymer and sodium alginate in the composition of the present invention are preferably those that are not substantially crosslinked by polyvalent metal ions. The content of the carboxyvinyl polymer or sodium alginate is preferably 3 to 15% by mass and more preferably 10 to 13% by mass as the mass% in all components excluding the solvent in the coating composition of the present invention. Or
The content of the carboxyvinyl polymer or sodium alginate is preferably 3 to 20% by mass as the mass% of all components excluding the solvent in the coating composition of the present invention.
The mass% or 8-18 mass% is more preferable, and 9-17 mass% is further more preferable. The ratio with respect to all the components in the coating of the oral composition of the present invention (hereinafter sometimes referred to as a coating film) is also the same.
In the present specification, the polyvalent metal compound is calcium, magnesium, aluminum,
It means a pharmaceutically acceptable water-soluble salt of a polyvalent metal such as zinc. Specifically, calcium chloride, magnesium chloride, aluminum chloride, aluminum sulfate, potassium alum, iron chloride alum, ammonium alum, ferric sulfate, aluminum hydroxide, aluminum silicate, aluminum phosphate, iron citrate, magnesium oxide , Calcium oxide, zinc oxide, zinc sulfate or hydrates thereof. Preferred is calcium chloride or a hydrate thereof, and more preferred is calcium chloride dihydrate. Specifically, the polyvalent metal ions generated from the polyvalent metal compound include calcium ions, magnesium ions,
Aluminum ions, divalent or trivalent iron ions, zinc ions and the like can be mentioned. Preferably, it is a calcium ion.
The blending amount of the polyvalent metal compound used in the present invention is preferably 2 to 15% by mass with respect to the first thickener selected from the group consisting of carboxyvinyl polymer and sodium alginate. More preferably, it is 2-11 mass%. Or the compounding quantity of the polyvalent metal compound used for this invention is 0.1-1 mass% preferably as a mass% in all the components except the solvent in the composition for coating of this invention, More preferably, it is 0. .2 to 0.7% by mass.
The xanthan gum used in the present invention is not particularly limited, but the displayed viscosity is 600 mPa ·
s or more (1% / 1% KCl solution, 25 ° C.) can be preferably used. Furthermore, the thing with a display viscosity of 800-1600 mPa * s is preferable. More specifically, as a xanthan gum, a commercially available product, for example, Keltrol CG-T (trade name) (Tricrystal, display viscosity: 1555
mPa · s), SAN ACE (trade name) (San-Eigen FFI, display viscosity: 1600m
Pa.s) can be used.
The guar gum used in the present invention is not particularly limited, but those having a displayed viscosity of 600 mPa · s or more (1% / 1% KCl solution, 25 ° C.) can be preferably used. Furthermore, the displayed viscosity is 80
It is preferably 0 to 1600 mPa · s (1% / 1% KCl solution, 25 ° C.). More specifically, as the guar gum, commercially available products such as guar gum RG100 (trade name) (MR Polysaccharide, display viscosity: 1100 mPa · s) can be used. Bistop D-2029 (trade name) (San-Eigen F.F.I., display viscosity: about 450 m
Pa.s (0.5%)) can also be used.
Xanthan gum, guar gum and sodium alginate are the second thickeners, and the addition of the second thickener creates appropriate adhesion between the tablets, making it easier to swallow the tablets together in the mouth. Become. The content of at least one or more second thickeners selected from the group consisting of xanthan gum, guar gum and sodium alginate in the coating film can be adjusted as appropriate according to the composition of the other components. In order to bring the dose, 10 to 40% by mass is preferable, and 20 to 30% by mass is more preferable.

Combination of the first thickener and the second thickener in the coating composition and the oral composition of the present invention (provided that the second thickener is used when the first thickener is sodium alginate). As the agent is not sodium alginate), the following combinations can be exemplified.
(1) Combination of first thickener: carboxyvinyl polymer and second thickener: xanthan gum;
(2) first thickener: a combination of carboxyvinyl polymer and second thickener: guar gum;
(3) Combination of first thickener: carboxyvinyl polymer and second thickener: sodium alginate;
(4) first thickener: a combination of carboxyvinyl polymer and second thickener: xanthan gum and guar gum;
(5) First thickener: carboxyvinyl polymer and second thickener: xanthan gum and sodium alginate combination:
(6) first thickener: a combination of carboxyvinyl polymer and second thickener: guar gum and sodium alginate;
(7) first thickener: a combination of carboxyvinyl polymer and second thickener: xanthan gum, guar gum and sodium alginate;
(8) Combination of first thickener: sodium alginate and second thickener: xanthan gum;
(9) a first thickener: a combination of sodium alginate and a second thickener: guar gum; and
(10) First thickener: Combination of sodium alginate and second thickener: xanthan gum and guar gum.

The following combination can be illustrated as a combination of the 1st thickener and the 2nd thickener in the preferable aspect of this invention.
(1) Combination of first thickener: carboxyvinyl polymer and second thickener: xanthan gum;
(2) first thickener: a combination of carboxyvinyl polymer and second thickener: guar gum;
(3) Combination of first thickener: carboxyvinyl polymer and second thickener: sodium alginate;
(4) first thickener: combination of sodium alginate and second thickener: xanthan gum; and
(5) Combination of first thickener: sodium alginate and second thickener: guar gum.

In a further preferred embodiment of the present invention, the combination of the first thickener and the second thickener is (1)
A combination of a first thickener: carboxyvinyl polymer and a second thickener: xanthan gum.

A first selected from the group consisting of carboxyvinyl polymer and sodium alginate
An oral composition coated with a coating composition comprising a thickener, a polyvalent metal compound, and at least one second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate The surface layer of (eg, tablet, etc.) is rapidly gelled by a small amount of water or saliva, and at the same time, the viscosity of the carboxyvinyl polymer and / or sodium alginate is crosslinked by polyvalent metal ions generated from the polyvalent metal compound. By increasing and forming a jelly-like relatively hard gel, it becomes easy to slip on the mucous membrane and improves swallowability. At the same time, the gelled film shows an unpleasant taste masking effect by suppressing drug elution for a short time until swallowing. When used in a multi-unit described later, the tablets are well-organized in the oral cavity, and the swallowability is further improved.

Sucralose that can be used in the present invention is a sweetener widely used as a substitute for sucrose. The content of sucralose in the coating film (mass% based on all components excluding the solvent in the coating film) is preferably 0.01 to 5 mass%, preferably 0.5 to 1 mass%.
Or 0.1-2 mass% is more preferable. Sucralose that can be used in the present invention is:
It is thought that the effect which improves the unpleasant taste masking effect further is shown.

The sugar or sugar alcohol that can be used in the present invention has a solubility at 20 ° C. of 30 or more. Preferably it is 50 or more. Solubility means the maximum mass (g) of a solute that dissolves in 100 g of water. Preferred sugars or sugar alcohols that can be used in the present invention include trehalose, maltose, erythritol, maltitol (reduced maltose starch syrup)
Etc. Erythritol and maltitol, which feel moderate sweetness when put in the mouth, are preferable in terms of taking feeling. In addition, erythritol, maltitol, and trehalose have low hygroscopicity and are particularly preferable from the viewpoint of storage stability of the preparation. 10-50 mass% is preferable and, as for content (mass% with respect to all the components except the solvent in a coating film) of sugar or sugar alcohol in a coating film, 30-40 mass% is more preferable.
A sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more that can be used in the present invention accelerates the swelling of the gel by the thickener. Furthermore, this is considered to promote the disintegration of the gel and improve the drug dissolution.
The HPMC used in the present invention is not particularly limited, but preferably has a viscosity of 100 mPa · s or less, more preferably 10 mPa · s or less. More specifically, HPMC is commercially available, for example, TC-5E (trade name) (Shin-Etsu Chemical Co., Ltd., display viscosity: 3 mPa ·
s), TC-5R (trade name) (Shin-Etsu Chemical, display viscosity: 6 mPa · s), and the like can be used.
The content of HPMC in the coating film (mass% relative to all components excluding the solvent in the coating film) is preferably 5 to 35 mass%, more preferably 10 to 30 mass%. More preferably, it is 10-20 mass% or 13-25 mass%.
HPMC promotes the disintegration of the gel by combining with a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more in the oral cavity as compared with the case of the sugar or sugar alcohol alone. This can prevent a simple increase in the sugar or sugar alcohol when it is necessary to disintegrate the gel at an early stage.
As described above, HPMC and a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more show a synergistic effect when used in combination, and promote the disintegration of the gel. As a result, when the gel is coated on the drug nucleus, improvement of drug dissolution is effective. The blending ratio (mass ratio) of HPMC and the sugar or sugar alcohol is preferably 1: 1 to 1: 4, more preferably 1: 2 to 1: 3.

The thickener used in the fifth to eighth aspects of the present invention means a substance that gels by contact with moisture, and is not particularly limited as long as it is a substance exhibiting such properties. The metal crosslinking thickener and the second thickener described in the description of the first to fourth aspects are included. More specifically, carboxyvinyl polymer, xanthan gum, starch and derivatives thereof, agar, sodium alginate, arabinogalactan, galactomannan, cellulose and derivatives thereof, carrageen, dextran, tragacanth, gelatin, pectin, hyaluronic acid, guar gum, gellan gum , Collagen, casein and the like.
Thickeners may be used alone or in combination of several kinds, and a combination of two or more containing a metal crosslinking thickener is preferred. As a preferred example, a combination of one or more selected from carboxyvinyl polymer and sodium alginate as a metal crosslinking thickener and one or more selected from xanthan gum, guar gum and sodium alginate (excluding combinations of the same substances) is preferable. Can be mentioned.
The coating composition of the present invention and the oral composition having the coating of the present invention may further contain hydroxypropylcellulose (hereinafter sometimes referred to as HPC) and the like. Since HPC can be dissolved in alcohol to obtain an appropriate viscosity, when the coating composition is dispersed in ethanol and spray coating is performed, fast sedimentation of particles can be suppressed, which is advantageous in maintaining uniformity. It is. Furthermore, it can help adhere particles to the tablet surface as a binder, increase coating efficiency and form a smooth film. For this reason, adding a certain amount of HPC to the coating composition is advantageous for the production of an oral composition having a coating.
Although it does not specifically limit as HPC which can be used for this invention, A low viscosity thing is preferable and a thing below 10 mPa * s (2%, 20 degreeC) is preferable. More specifically, as HPC, a commercially available product such as HPC-L (trade name) (Nippon Soda, display viscosity: 6.0 to 1)
0 mPa · s), HPC-SL (trade name) (Nippon Soda, display viscosity: 3.0 to 5.9 mPa
S) can be used. The content of HPC in the coating film (mass in all components excluding the solvent in the coating film) is preferably 0.1 to 15% by mass, and 5 to 15% by mass.
% Or 0.1 to 12% by mass is more preferable. The content of HPC in the coating composition (coating solution) of the present invention used for spray coating is 0.1 to 5% by mass, preferably 0.2 to 3% by mass of the total mass of the coating solution, Preferably 0.5-1
. 8% by mass.

As a solvent that can be used for preparing the coating composition of the present invention, water, alcohol, a mixed solvent of water and alcohol, or the like can be used. Among these, alcohol is preferable. As the alcohol, ethanol or absolute ethanol is preferable. Here, ethanol, ethanol _(C 2 _{H 6} O) contained more than 95.1～96.9Vol%, absolute ethanol refers to those containing more ethanol 99.5 vol%. Preferably, it is 95.1-96.9 vol% or more ethanol.
Glycerin may be included in the preparation of the coating composition of the present invention. Glycerin is
It is considered that it acts as a plasticizer in the coating composition and has an effect of promoting the swelling of the gel when the coating film comes into contact with water. Although it does not specifically limit as glycerol used for the composition of this invention, In the case of fixed_quantity | quantitative, glycerin 98.0 with respect to the converted dehydrated product.
Concentrated glycerin containing at least% is preferred. When glycerin is included, the content thereof is 0.1 to 5% by mass, preferably 0.5 to 3% by mass, more preferably 0.5 to 1% by mass, based on the total mass of the coating composition including a solvent. %.
In preparing the coating composition, water or an aqueous solvent such as a water / alcohol mixed solvent may be used depending on the type or amount of the thickener used. When an aqueous solvent is used as the coating composition of the present invention, if the concentration of the coating composition is increased, the viscosity may increase and the operability may deteriorate, so a coating method according to the properties of the coating composition as appropriate. It is necessary to select.

The coating composition of some embodiments of the present invention comprises:
Carboxyvinyl polymer (eg, Carbopol 974P (trade name)) as the first thickener
;
Calcium chloride as the polyvalent metal compound;
Xanthan gum as a second thickener;
Sucralose;
HPMC (eg, TC-5E (trade name));
Erythritol as a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more;
HPC (eg, HPC-L (trade name)); and ethanol as a solvent.
Preferably, in the coating composition, the content of carboxyvinyl polymer (mass in all components excluding solvent, hereinafter the same) is 3 to 20% by mass, more preferably 9 to 17%.
The content of calcium chloride is 0.1 to 1% by mass, more preferably 0.2 to 0%.
. 7% by mass, and the xanthan gum content is 10 to 40% by mass, more preferably 20 to 20% by mass.
30% by mass, and the sucralose content is 0.01 to 5% by mass, more preferably 0.5 to
1 mass%, HPMC content is 5 to 35 mass%, more preferably 10 to 20 mass%, erythritol content is 10 to 50 mass%, more preferably 30 to 40 mass%, The content of HPC is 0.1 to 15% by mass, more preferably 5 to 15% by mass.
More preferably, in the coating composition, the content of carboxyvinyl polymer (mass in all components excluding solvent, hereinafter the same) is 12.7 mass%, and the content of calcium chloride is 0.5 mass. Xanthan gum content is 25.3% by weight,
The sucralose content is 0.8% by mass, the HPMC content is 15.2% by mass, the erythritol content is 35.4% by mass, and the HPC content is 10.1% by mass. is there.
In another more preferable aspect, in the coating composition, the content of carboxyvinyl polymer (mass in all components excluding solvent, hereinafter the same) is 9.4% by mass, and the content of calcium chloride is 0. .4% by mass and the xanthan gum content is 26.3% by mass
The sucralose content is 0.9% by mass, the HPMC content is 15.8% by mass, the erythritol content is 36.8% by mass, and the HPC content is 10.5%.
% By mass.
In another more preferred aspect, in the coating composition, the content of carboxyvinyl polymer (mass in all components excluding solvent, hereinafter the same) is 16.7% by mass,
The content of calcium chloride is 0.6% by mass, the content of xanthan gum is 23.4% by mass, the content of sucralose is 0.8% by mass, and the content of HPMC is 13.9% by mass. The erythritol content is 33.4% by mass, and the HPC content is 11.
1% by mass.
In another more preferable aspect, in the coating composition, the content of carboxyvinyl polymer (mass in all components excluding solvent, hereinafter the same) is 9.3% by mass, and the content of calcium chloride is 0. 2% by mass, and the xanthan gum content is 26.1% by mass.
The sucralose content is 0.9% by mass, the HPMC content is 15.5% by mass, the erythritol content is 37.3% by mass, and the HPC content is 10.6%.
% By mass.

As a method for preparing the coating composition of the first aspect of the present invention, the components of the coating composition of the present invention can be dissolved or uniformly dispersed in water, alcohol, or a mixed solvent of water and alcohol. That's fine. Preferably, a method of uniformly dispersing other constituents in an alcohol solution in which a polyvalent metal compound is dissolved is preferable. Specifically, in an alcohol solution in which a polyvalent metal compound is dissolved, at least one second thickener (preferably xanthan gum) selected from the group consisting of xanthan gum, guar gum and sodium alginate, and a carboxyvinyl polymer and A first selected from the group consisting of sodium alginate
A thickener (preferably a carboxyvinyl polymer) (but when the first thickener is sodium alginate, the second thickener is not sodium alginate), preferably (i) HPMC and / or sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more, or (ii) at least one selected from the group consisting of sucralose, HPMC and sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more What is necessary is just to prepare by disperse | distributing the fine powder containing the above uniformly. More preferably, ethanol is used as a solvent.
More preferably, at least one second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate (more preferably xanthan gum), a first thickener which is a metal crosslinking thickener (more preferably Is a thickener selected from the group consisting of carboxyvinyl polymer and sodium alginate, more preferably carboxyvinyl polymer) (provided that the second thickener is when the first thickener is sodium alginate). The preparation is not sodium alginate), HPMC, and a fine suspension of sugar or sugar alcohol having a solubility of 30 or more at 20 ° C is uniformly dispersed in a mixed solution of ethanol and glycerin. A coating solution is prepared by adding a solution in which a metal compound is dissolved in ethanol. .
More preferably, at least one second thickener (more preferably xanthan gum) selected from the group consisting of xanthan gum, guar gum and sodium alginate, more preferably a first thickener which is a metal crosslinking thickener (more preferably Is a thickener selected from the group consisting of carboxyvinyl polymer and sodium alginate, more preferably carboxyvinyl polymer), provided that the second thickener is sodium alginate.
The thickener is not sodium alginate), sucralose, HPMC, and a sugar or sugar alcohol fine powder with a solubility of 30 or more at 20 ° C. are uniformly dispersed in a mixture of ethanol and glycerin separately. The coating solution is prepared by adding a solution in which a polyvalent metal compound is dissolved in ethanol.

As a method for preparing the coating composition according to the fifth aspect of the present invention, HPMC and a sugar or sugar alcohol having a solubility of 30 or more at 20 ° C. are contained in a suspension or dissolved solution in which a thickener is dispersed. Prepare by dissolving or evenly dispersing fine powder. As above, alcohol is preferably used as the solvent. More preferred is ethanol.
It is preferable to make the particle diameters of the constituents finer using a pulverizer such as a jet mill, if necessary, so that the suspension for coating of the present invention is uniformly dispersed. The particle diameter is preferably 35 μm or less, more preferably 25 μm or less, and even more preferably 10 μm or less as a median diameter (D50: a diameter in which the larger side and the smaller side are equal when powder is divided into two from a certain particle size). preferable.
As a method of coating the coating composition of the present invention on a drug nucleus or oral solid, a known coating technique can be used, and it is not particularly limited. For example, a pan coating device, a fluidized bed coating device, a ventilating rotary drum coating device, or the like can be used. In particular, a ventilating rotary drum coating apparatus is suitable for coating a mini-tablet described later. Further, by performing spray coating or powder coating using these devices, it is possible to coat drug cores or oral solids. A preferred coating method is spray coating. In particular, it is preferable to supply continuously using a spray nozzle. It can be coated with a single coating on drug cores or oral solids. However, the coating may be performed a plurality of times without being limited to a single time.
When alcohol is used as a solvent as described above, the first thickener such as carboxyvinyl polymer and sodium alginate is not substantially cross-linked by polyvalent metal ions, and a coating composition having a low viscosity is obtained. Can be obtained. For this reason, spray coating can be performed easily. Moreover, since it is an alcohol solution, drying after coating can be performed in a short time, which is advantageous in production.
When the oral composition of the second aspect of the present invention is obtained by coating using alcohol as a solvent as described above, the first thickening of carboxyvinyl polymer, sodium alginate and the like in the coating film is performed. The agent is in a state that is not substantially cross-linked by polyvalent metal ions as long as moisture is not in contact with the film.
Oral compositions can also be prepared using water as a solvent. When water is used as the solvent, the first thickener such as carboxyvinyl polymer and sodium alginate is substantially cross-linked by the polyvalent metal ions, resulting in a coating composition having a high viscosity. Therefore, by coating a drug nucleus or solid for oral use with this coating composition, it is selected from the group consisting of carboxyvinyl polymer cross-linked by polyvalent metal ions, sodium alginate cross-linked by polyvalent metal ions, etc. An oral composition according to the ninth aspect of the present invention is produced.
The amount of the solid component of the coating composition of the present invention is preferably 2 to 30% by mass, more preferably 3 to 15% by mass with respect to the drug core or oral solid to be coated. The thickness of the coating film of the coated oral composition thus obtained is 10 μm to
It is 100 micrometers, Preferably, it is 20-70 micrometers.

The content of the first thickener selected from the group consisting of carboxyvinyl polymer and sodium alginate of the coating composition of the present invention (coating solution) used for spray coating is, if present in the coating solution. The total mass of the coating liquid is, for example, 0.5 to 5% by mass, preferably 0.5 to 4% by mass, and more preferably 0.
It is 5 to 3% by mass.
The content of at least one second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate is, for example, 1 to 5% by mass of the total mass of the coating liquid, when present in the coating liquid , Preferably 1-4% by weight, more preferably
3-4% by mass.
When the content of the entire thickener is present in the coating liquid, it is, for example, 1.5 to 10% by mass, preferably 1.5 to 8% by mass, and more preferably 3.5%, based on the total mass of the coating liquid.
-7% by mass.
When the content of HPMC is present in the coating solution, it is 1 to 10% by weight, preferably 1 to 5% by weight, more preferably 1.5 to 3.5% by weight, based on the total weight of the coating solution.
It is.
When the sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more in the coating composition (coating liquid) of the present invention used for spray coating is present in the coating liquid, it is 1 to 10% by mass of the total mass. , Preferably 1-6% by weight, more preferably 3-6
Mass% is included.
When the content of sucralose is present in the coating solution, it is 0.001 to 0.7% by mass, preferably 0.01 to 0.3% by mass, more preferably 0.00% by mass of the total mass of the coating solution. It is 05-0.2 mass%.

The coating composition of the present invention includes a kit in which the components to be included are combined, or a combination or kit in which the components to be included are divided into two or more. For example, a first thickener and a second thickener, as required (i) HPMC and sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more, or (ii) solubility of sucralose, HPMC and 20 ° C. 3
A combination of a coating composition (A) containing at least one selected from the group consisting of zero or more sugars or sugar alcohols, and a coating composition (B) containing a polyvalent metal compound. Also, a kit comprising a combination of the coating composition (A) and the polyvalent metal compound (C), a combination composition (D) of the first thickener and the second thickener, HPMC and 20 ° C. A kit comprising a coating composition (E) comprising a sugar or sugar alcohol having a solubility of 30 or more and a polyvalent metal compound (C), a combined composition of a first thickener and a second thickener (D),
A composition for coating (E ′) comprising at least one selected from the group consisting of sucralose, HPMC, and a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more, and a polyvalent metal compound (C) Examples include kits.
The components contained in these combinations or kits may be combined and coated onto the drug core or oral solid as described above. Alternatively, each coating composition dissolved or uniformly dispersed in an alcohol solvent or water may be sequentially coated on the drug core or oral solid. At this time, the solvent may be changed for coating. In the above example, the composition (A) dissolved or uniformly dispersed in an alcohol solvent is first coated on the drug core or oral solid, and then the composition (B) dissolved in water is then coated. it can. In this case, at the boundary between the composition (A) and the composition (B), the oral composition according to the ninth aspect of the present invention includes a coating in which the first thickener is partially cross-linked by polyvalent metal ions. Things are manufactured.

The oral composition of the second aspect of the present invention can be obtained by coating the drug core with the coating composition of the first aspect of the present invention. However, the present invention is not limited to this method, and a first carboxyvinyl polymer, sodium alginate, or the like is formed on the surface of the drug core.
Thickeners, polyvalent metal compounds, and second thickeners such as xanthan gum, guar gum, sodium alginate, etc. (provided that when the first thickener is sodium alginate, the second thickener is alginic acid Any oral composition having (not sodium) is included in the oral composition of the second aspect of the present invention.
The oral composition of the sixth aspect of the present invention can be obtained by coating the drug core with the coating composition of the fifth aspect of the present invention. However, the present invention is not limited to this method, and any oral composition having a thickener, a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more and HPMC on the surface of the drug core may be used. In the composition for oral use of the sixth aspect.
In the present invention, examples of the drug core containing the active ingredient used in the oral composition include solid preparations such as a tablet core, a pill core, a capsule core, a pellet core, and a granule core. The oral solid material is not particularly limited as long as it includes a solid drug nucleus and is a solid material for other oral use. In a preparation with a large dose, a mini tablet having a form that can avoid the enlargement of the preparation and reduce the drug content per tablet and minimize the bulk is preferable as the drug core. Minitablets can be manufactured with normal equipment.
The mini-tablet used in the present specification is a form of a tablet and has a diameter and thickness of 6 m.
It refers to a granular solid preparation of m or less. In the case of an active ingredient with a large dose, if the diameter is 3 to 4 mm, the number of doses per dose is about 20 to 100. In the present specification, a single dose in an oral preparation having 10 or more doses per dose is referred to as a multi-unit. Preferably, it is a granular tablet having a diameter and thickness of 0.5 to 5 mm, more preferably 2 to 4 mm.

In the oral composition of the present invention, a seal coating may be provided between a drug core containing an active ingredient or an oral solid and a coating (sometimes referred to herein as “overcoating”). . The oral composition of the present invention having a seal coating comprises:
The coating composition of the present invention can be obtained by coating a seal coat drug nucleus having a seal coating.
Seal coating the drug core prevents the drug core components from moving to the coating layer during storage and causing compounding changes with the coating layer components. Thus, it is expected to prevent the unpleasant taste masking effect at the time of taking by the coating from being attenuated or to enhance the unpleasant taste masking effect at the time of taking by the coating.
The seal coating is obtained by coating a seal coating composition on a drug core containing an active ingredient using a known coating technique. The seal coating composition only needs to prevent migration of the drug core component to the coating during storage of the oral composition. For example, (i) HPMC, HPC, ethyl cellulose, polyvinyl pyrrolidone, pullulan , At least one selected from the group consisting of acrylic acid ester / methacrylic acid ester copolymers, or (ii) HPMC, HPC,
Ethyl cellulose, polyvinyl pyrrolidone, pullulan, acrylic acid / methacrylic acid ester copolymer, pregelatinized starch, erythritol, macrogol 6000 (trade name)
), Talc, light anhydrous silicic acid and the like, and a composition containing at least one selected from the group consisting of.
As a solvent that can be used for preparing the seal coating composition, water, alcohol, a mixed solvent of water and alcohol, or the like can be used.
The amount of the solid component of the seal coating composition is preferably 1 to 10% by mass, more preferably 2 to 5% by mass, based on the drug core or oral solid to be coated. The thickness of the seal coating film of the oral composition containing the seal coating thus obtained is
It is 10-80 micrometers, Preferably, it is 20-40 micrometers.
The oral composition of some embodiments of the present invention does not have a seal coating.

In the oral composition of the present invention, a middle coating may be further provided between the seal coating and the coating. The oral composition of the present invention having a middle coating comprises:
The coating composition of the present invention can be obtained by coating a middle coat-seal coat drug core having a seal coating and a middle coating.
By providing a middle coating on the drug core, it is possible to increase the drug elution rate while maintaining an unpleasant taste masking effect.
The middle coating is obtained by coating the middle coating composition on a seal coat drug core having a seal coating using known coating techniques. The middle coating composition only needs to enhance the disintegration property of the overcoating which is the coating composition of the present invention. For example, the aforementioned sugar or sugar alcohol having a solubility of 20 or more at 20 ° C., HPMC having a low viscosity, etc. A composition containing at least one selected from the group consisting of, preferably at least one selected from the group consisting of erythritol, TC-5E (Shin-Etsu Chemical) and the like.
As a solvent that can be used for preparing the middle coating composition, water, alcohol, a mixed solvent of water and alcohol, or the like can be used.
The amount of the solid component in the middle coating composition is preferably 1 to 10% by mass, more preferably 2 to 5% by mass, based on the drug core or oral solid to be coated. The thickness of the middle coating film of the oral composition containing the middle coating thus obtained is
It is 10-80 micrometers, Preferably, it is 20-40 micrometers.
The oral composition of some embodiments of the present invention does not have a middle coating.

The oral composition of the present invention is, for example,
(I) drug nucleus / overcoating;
(Iii) drug nucleus / seal coating / overcoating; or (iii) drug nucleus / seal coating / middle coating / overcoating;
Preferably,
(Iii) drug nucleus / seal coating / overcoating; or (iii) drug nucleus / seal coating / middle coating / overcoating;
More preferably,
(Ii) Consists of drug core / seal coating / overcoating.

The oral composition of some embodiments of the present invention comprises:
A drug core containing an active ingredient (preferably a tablet core, more preferably a mini-tablet);
In the drug nucleus,
Carboxyvinyl polymer (eg, Carbopol 974P (trade name)) as the first thickener
,
Calcium chloride as a polyvalent metal compound,
Xanthan gum as a second thickener,
Sucralose,
HPMC (eg, TC-5E (trade name)),
Erythritol as a sugar or sugar alcohol having a solubility at 20 ° C. of 30 or more, and HPC (eg, HPC-L (trade name)),
A coating comprising:
Have
There is a further seal coating between the drug core and the coating,
There is no middle coating between the seal coating and the coating.
Preferably, in the coating composition, the content of the carboxyvinyl polymer of the overcoating (mass in all components excluding solvent, hereinafter the same) is 3 to 20% by mass,
More preferably, it is 9-17% by mass, the content of calcium chloride is 0.1-1% by mass, more preferably 0.2-0.7% by mass, and the content of xanthan gum is 10-40% by mass.
More preferably, it is 20-30% by mass, and the content of sucralose is 0.01-5% by mass,
More preferably, it is 0.5-1% by mass, the HPMC content is 5-35% by mass, more preferably 10-20% by mass, and the erythritol content is 10-50% by mass, more preferably 30%. To 40% by mass, and the HPC content is 0.1 to 15% by mass, more preferably 5 to 5% by mass.
15% by mass.
In some aspects of the invention, the seal coating comprises HPMC and Macrogol 6
000 (product name) is included. In this case, preferably, the content of HPMC in the seal coating (mass in all components excluding seal coating solvent, hereinafter the same) is 60 to 99% by mass,
More preferably, it is 90 to 98% by mass, and the content of Macrogol 6000 (trade name) is 1 to
It is 40 mass%, More preferably, it is 2-10 mass%.
In some other aspects of the invention, the seal coating comprises erythritol, α
Contains modified starch. In this case, the content of erythritol in the seal coating is preferably 60 to 99% by mass (mass in all components excluding the solvent of the seal coating, hereinafter the same).
More preferably, it is 80-95 mass%, and content of pregelatinized starch is 1-40 mass%, More preferably, it is 5-20 mass%.
In some other aspects of the invention, the seal coating comprises HPMC and erythritol. In this case, preferably, the HPMC content of the seal coating (mass in all components excluding the solvent of the seal coating, hereinafter the same) is 5 to 45% by mass, more preferably 20 to 40% by mass. Content is 55-95 mass%, More preferably, it is 60-80 mass%.

Preferably, in the above oral composition, the seal coating contains HPMC and Macrogol 6000 (trade name).
In this case, in the above oral composition, the content of the carboxyvinyl polymer of the overcoating (mass in all components excluding the solvent of the overcoating, hereinafter the same) is 12.
7 mass%, calcium chloride content is 0.5 mass%, xanthan gum content is 25.3 mass%, sucralose content is 0.8 mass%, HPMC content Is 15.2% by mass, the erythritol content is 35.4% by mass, and HPC
The content of is 10.1% by mass. The content of HPMC in the seal coating (mass in all components excluding the solvent in the seal coating, hereinafter the same) is 95.2% by mass, and the content of Macrogol 6000 (trade name) is 4.8 mass. %.

Preferably, in the above oral composition, the seal coating contains HPMC and Macrogol 6000 (trade name).
At this time, in the above oral composition, the content of the carboxyvinyl polymer of the overcoating (mass in all components excluding the solvent of the overcoating, hereinafter the same) is 9.4.
The content of calcium chloride is 0.4% by mass, the content of xanthan gum is 26.3% by mass, the content of sucralose is 0.9% by mass, and the content of HPMC is The content of erythritol is 36.8% by mass, and the content of HPC is 10.5% by mass. The content of HPMC in the seal coating (mass in all components excluding the solvent in the seal coating, hereinafter the same) is 95.2% by mass, and the content of Macrogol 6000 (trade name) is 4.8 mass. %.

Preferably, in the above oral composition, the seal coating comprises erythritol,
Contains pregelatinized starch.
At this time, in the above oral composition, the content of carboxyvinyl polymer in the overcoating (mass in all components excluding overcoating solvent, hereinafter the same) is 16.
7% by mass, calcium chloride content is 0.6% by mass, xanthan gum content is 23.4% by mass, sucralose content is 0.8% by mass, HPMC content Is 13.9% by mass, the erythritol content is 33.4% by mass, and HPC
The content of is 11.1% by mass. The content of erythritol in the seal coating (mass in all components excluding the solvent in the seal coating, hereinafter the same) is 90% by mass,
The content of pregelatinized starch is 10% by mass.

Preferably, in the above oral composition, the seal coating contains HPMC and erythritol.
At this time, in the oral composition, the content of the overcoating carboxyvinyl polymer (mass in all components excluding the solvent, hereinafter the same) was 9.3% by mass, and the content of calcium chloride was 0.00. 2% by mass, xanthan gum content is 26.1% by mass, sucralose content is 0.9% by mass, HPMC content is 15.5% by mass, erythritol content is It is 37.3 mass%, and the content of HPC is 10.6 mass%.
It is. Further, the content of HPMC in the seal coating (mass in all components excluding the solvent in the seal coating, hereinafter the same) is 29.4% by mass, and the content of erythritol is 7
0.6% by mass.

The drug nucleus or oral solid used in the present invention is prepared by blending a pharmaceutical carrier commonly used in the pharmaceutical technical field in addition to a desired drug as an active ingredient. As such pharmaceutical carriers, those known in the pharmaceutical technical field can be widely used, for example, lactose, sucrose, mannitol, sodium chloride, glucose, starch, calcium carbonate, kaolin, crystalline cellulose, silicate and other excipients, Water, ethanol, simple syrup, glucose solution, starch solution, gelatin solution,
Binding agents such as carboxymethylcellulose, carboxymethylcellulose Na, shellac, methylcellulose, HPMC, HPC, polyvinyl alcohol, gelatin, dextrin, pullulan; citric acid, anhydrous citric acid, sodium citrate, sodium citrate dihydrate, anhydrous phosphoric acid PH adjusters such as sodium monohydrogen, anhydrous sodium dihydrogen phosphate, sodium hydrogen phosphate, anhydrous sodium dihydrogen phosphate; carmellose calcium, low-substituted hydroxypropycellulose, carmellose, croscarmellose sodium, partial alpha-formation Starch, dried starch, carboxymethyl starch sodium, crospovidone,
Disintegrants such as polysorbate 80; absorption enhancers such as sodium lauryl sulfate; purified talc,
Examples thereof include lubricants such as stearate, polyethylene glycol and colloidal silicic acid. When carboxymethyl starch sodium is used, disintegration may be improved. Examples include Primogel (Matsuya Chemical) Exp Protab (Kimura Sangyo) and Glycolys (Rocket Japan).
When a mini-tablet is used as a coating preparation and it is administered as a multi-unit, the tablet surface layer gels after contact with water, and at the same time, carboxyvinyl polymer and / or alginic acid is generated by polyvalent metal ions generated from the polyvalent metal compound The first such as sodium
When the thickener is cross-linked, the viscosity increases, and by forming a jelly-like relatively hard gel, it becomes slippery and the unity between tablets is well swallowed. Further, since the release of the drug is suppressed for a short time by the formed gel layer, masking of unpleasant taste is more effective.
In the oral composition of some embodiments of the present invention, the drug core (preferably a tablet core, more preferably a mini-tablet) comprises levofloxacin hydrate as an active ingredient,
Contains crystalline cellulose, sodium carboxymethyl starch, pregelatinized starch and sodium stearyl fumarate. Preferably, the content of levofloxacin hydrate in the tablet core (
The mass in all components excluding the solvent of the tablet core, hereinafter the same) is 7 to 70% by mass, more preferably 35
-70 mass%, the content of crystalline cellulose is 1-20 mass%, more preferably 5-7
The content of sodium carboxymethyl starch is 5 to 30% by mass, more preferably 15 to 20% by mass, and the content of pregelatinized starch is 0.3 to 20% by mass, more preferably 1%. -5% by weight, and the content of sodium stearyl fumarate is 0.3-2
It is 0 mass%, More preferably, it is 1-5 mass%. Particularly preferably, the content of levofloxacin hydrate in the tablet core (mass in all components excluding the solvent of the tablet core, hereinafter the same) is 69.7% by mass, and the content of crystalline cellulose is 6.2. The content of sodium carboxymethyl starch is 17.7% by weight, the content of pregelatinized starch is 2.7% by weight, and the content of sodium stearyl fumarate is 3.7% by weight. It is.
In an oral composition according to some other aspects of the present invention, the drug core (preferably a tablet core, more preferably a mini-tablet) contains valacyclovir hydrochloride as an active ingredient, and further contains a partially pregelatinized starch, α Modified starch, talc and sodium stearyl fumarate, and optionally sodium carboxymethyl starch. Preferably, the drug nucleus has a content of valacyclovir hydrochloride (mass in all components excluding the solvent of the tablet nucleus, hereinafter the same) of 7
-80 mass%, more preferably 35-80 mass%, and the content of partially pregelatinized starch is 2
-40 mass%, more preferably 5-20 mass%, the content of sodium carboxymethyl starch is 0-30 wt%, more preferably 0-15 wt%, the content of pregelatinized starch is 0.3 -30% by mass, more preferably 1-20% by mass, and the content of talc is 0.
. It is 3 to 20% by mass, more preferably 1 to 5% by mass, and the content of sodium stearyl fumarate is 0.3 to 20% by mass, more preferably 1 to 5% by mass. Particularly preferably, the drug nucleus has a content of valacyclovir hydrochloride (mass in all components excluding the solvent of the tablet core, hereinafter the same) of 75.6% by mass, and the content of partially pregelatinized starch is 4 .6% by mass, the content of sodium carboxymethyl starch is 13.6% by mass, the content of pregelatinized starch is 2.0% by mass, and the content of talc is 2.7% by mass. The content of sodium stearyl fumarate is 1.4% by mass. Further, particularly preferably, the content of the drug nucleus is 75.6% by mass of the content of valacyclovir hydrochloride (mass in all components excluding the solvent of the tablet nucleus, hereinafter the same), and the content of the partially pregelatinized starch Is 18.7% by weight, the pregelatinized starch content is 1.5% by weight, the talc content is 2.7% by weight, and the sodium stearyl fumarate content is 1.4% by weight. %.
The description of the method for producing the oral composition of the fourth and eighth aspects of the present invention is as described above.
Moreover, the oral composition of the 3rd aspect and 7th aspect of this invention can be obtained with the manufacturing method described above. The oral composition of the third aspect of the present invention is a first composition such as carboxyvinyl polymer and sodium alginate in an alcohol solution in which a polyvalent metal compound is dissolved.
Thickener (preferably carboxyvinyl polymer) and a second thickener (preferably xanthan gum) such as xanthan gum, guar gum, sodium alginate, etc., provided that the second thickener is sodium alginate. The thickener is not sodium alginate) by spray coating the drug core containing the active ingredient, as described above. The thickener 1 is in a state where it is not substantially cross-linked by polyvalent metal ions as long as moisture is not in contact with the film. In addition, the oral composition of the present invention can be easily washed away with the alcohol solvent used. On the other hand, in an oral composition coated with a solution other than alcohol, for example, an aqueous solution as a solvent, the first thickener such as carboxyvinyl polymer in the coating film is substantially cross-linked with a polyvalent metal ion. Since it is in a state, it is not easy to wash off the coating.

Regarding ease of swallowing of the oral composition in the present invention, specifically, Test Example 1 described later
In the test method described in 1), that is, in the evaluation using a vertically fixed silicon tube (8 × 12) having a length of 5 cm with the lower end plugged with absorbent cotton (25 to 30 mg), in the tube for the filled oral composition Movement of the probe (spherical 6mm in diameter) inserted into the shaft (speed 8mm / sec)
, And the maximum stress required for the vertical movement distance of 40 mm). The oral composition of the present invention preferably has a maximum stress of 41 g or less, more preferably 30 g or less, and even more preferably 20 g or less. The area under the stress / distance curve is 6
What is 00 g · mm or less is preferable, more preferably 400 g · mm or less, and even more preferably 200 g · mm or less.
Regarding the unpleasant taste masking effect in the present invention, specifically, the test method described in Test Example 2 to be described later, that is, an oral composition containing an active ingredient in a vertical 2 mL plastic syringe and Test Example 2 is used. In the same manner, when the water heated to 37 ° C from the top is dropped at a flow rate of 2 mL / min for a certain time, for example, 30 seconds or 2 minutes, it is expressed by the concentration of the active ingredient in the liquid flowing out from the mouth of the syringe. Can do. The oral composition of the present invention is judged to be sufficiently masked for practical use if the concentration is below the threshold concentration of the unpleasant taste of the active ingredient when water is dropped for 30 seconds in the above test. . For example, in the case of levofloxacin hydrate, when levofloxacin concentration is 1,000 μg / mL or less when water is dropped for 30 seconds,
Unpleasant taste masking is good and preferable. Even in the case of a preparation taken without using water, if the concentration is below the threshold concentration of the unpleasant taste of the active ingredient in the above test, it is judged that the masking is sufficient for practical use. For example, levofloxacin hydrate The concentration is 100 μg /
mL or less, preferably 50 μg / mL or less, more preferably 10 μg / mL or less. In the case of valaciclovir hydrochloride, the concentration is, for example, 100 μg / mL or less, preferably 6
0 μg / mL or less, more preferably 20 μg / mL or less.
Regarding the dissolution property in the present invention, specifically, in the test example described in Test Example 3 described later, the Japanese Pharmacopoeia Disintegration Test Solution 1 by the Japanese Pharmacopoeia Dissolution Test Paddle Method and the evaluation at 50 rotations, 30 It can be expressed as the dissolution rate when minutes pass. The oral composition of the present invention preferably has an elution rate of 60% or more, more preferably 80% or more. More preferably, it is 90% or more, and there is no substantial dissolution delay, which satisfies the dissolution criteria for immediate-release tablets.

The active ingredient contained in the drug core used in the oral composition in the present invention is not particularly limited, but for the purpose of the present invention, a drug with a large single dose is particularly suitable. For example, the antibiotics amoxiline, cefuroxime axetil, cephalexin, fosfomycin, ceftazidime, ampicillin, cyclacillin, lenampicillin, cefotiam hexetyl, sultamicillin, vancomycin, polymyxin B, erythromycin, clarithromycin, tethromycin, azithromycin, josamycin, Midecamycin, rokitamycin, roxithromycin, kanamycin, ceftibbutene, chloramphenicol, cycloserine, rifabutin, synthetic antibacterial ofloxacin, enoxacin,
Levofloxacin, ciprofloxacin, norfloxacin, moxifloxacin, galenoxacin, lomefloxacin, nalidixic acid, linezolid, sulfa drugs salazosulfapyridine, antifungal drug voriconazole, itraconazole, antiviral drugs acyclovir, valacyclovir, fam Cyclovir, valganciclovir, nelfinavir, raltegravir, rabivudine, emtricitabine, ritonavir, ribavirin, abacavir, efavirenz, nelfinavir, tenofovir, disoproxil, darunavir,
Atazanavir, hyperlipidemic drug probucol, clofibrate, colestimide, cholestyramine, anthelmintic drug praziquantel, albendazole, antiprotozoal drugs tinidazole, metronidazole, branched chain amino acids, antidote Examples include activated carbon, 5-aminosalicylic acid for digestive organs, polycarbophil calcium, imatinib mesylate as an antineoplastic agent, mycophenolate mofetil as an immunosuppressant, and other drugs such as inosine planovex. . Furthermore, the present invention is not limited to these drugs, and the coating composition of the present invention can also be applied to traditional Chinese medicines, OTC drugs and health foods.

Next, although an example and a comparative example are shown and the present invention is explained still more concretely, the present invention is not limited to these.

(1) Manufacture of placebo mini tablet (plain tablet P):
The following ingredients were weighed, mixed and tableted to obtain about 25 mg of a placebo mini tablet having a diameter of 3.1 mm and a thickness of 3.1 mm / kg (about 80,000 tablets).
Lactose 2.050kg
Crystalline cellulose 0.519kg
Magnesium stearate 0.026kg

(2) Production of levofloxacin hydrate minitablets and valacyclovir hydrochloride minitablets:
Levofloxacin hydrate or valacyclovir hydrochloride is selected as a model drug having high water solubility and bitterness, and levofloxacin hydrate-containing mini tablets A to C (uncoated tablets A to C) and valacyclovir hydrochloride containing mini tablets D to G (elementary) Tablets D to G) were produced.
(i) Production of levofloxacin hydrate-containing mini tablet A (uncoated tablet A):
The following components were weighed, put into a stirring and mixing granulator (Paurec VG-25) and mixed, and granulated by adding 2000 g of an 8 w / w% HPC aqueous solution as a binder.
Levofloxacin hydrate 4.100kg
Crystalline cellulose 0.364kg
Carmellose 0.392kg
Sodium stearyl fumarate 0.108 kg
3. Powder obtained by drying the granulated product with a fluidized bed dryer (Paurec MP-01) and then sizing.
0.087 kg of sodium stearyl fumarate was added to 277 kg, mixed and compressed into tablets. About 24 mg / tablet of levofloxacin hydrate mini-tablets with a diameter of 3.1 mm and a thickness of 3.1 mm were added.
. 612 kg (about 150,500 tablets) were obtained.

(ii) Production of levofloxacin hydrate-containing mini tablet B (uncoated tablet B):
The following components were weighed, put into a stirring and mixing granulator (high speed mixer) and mixed, and water was added for granulation.
Levofloxacin hydrate 205.0g
Crystalline cellulose 18.2 g
Pregelatinized starch (SWELSTAR PD-1; Asahi Kasei) 19.6 g
Pregelatinized starch (SWELSTAR WB-1; Asahi Kasei) 9.0 g
5.4 g of sodium stearyl fumarate
Powder 23 obtained by drying the granulated product with a fluidized bed dryer (Paurec MP-01) and adjusting the size.
To 9.9 g, 4.9 g of sodium stearyl fumarate was added, mixed and compressed into tablets, and the diameter was 3.1.
About 24 mg / tablet of levofloxacin hydrate minitablet with a thickness of 3.1 mm about 220 mg / tablet
g (about 9,200 tablets) was obtained.

(iii) Production of levofloxacin hydrate-containing mini tablet C (uncoated tablet C):
<Manufacturing of 3kg scale>
The following components are weighed, put into a stirring and mixing granulator (Paurek VG-25) and mixed, and 5 w / w% pregelatinized starch (SWELSTARB-1; Asahi Kasei) aqueous solution as a binder.
Granulation was performed by adding 93 kg and 1.57 kg of water.
Levofloxacin hydrate 2.471 kg
Crystalline cellulose 0.220kg
Sodium carboxymethyl starch (primogel) 0.627kg
Sodium stearyl fumarate 0.065kg
2. Powder obtained by drying the granulated product with a fluidized bed dryer (Paurec MP-01) and then sizing.
095 kg of sodium stearyl fumarate 0.058 kg was added, mixed and compressed to obtain about 3 mg (about 125,000 tablets) of about 24 mg / tablet of levofloxacin hydrate mini-tablets having a diameter of 3.1 mm and a thickness of 3.1 mm. .

<Manufacturing of 50 kg scale>
The following components are weighed, mixed in a stirring and mixing granulator (Paurec VG-100), mixed, and 9.36 kg of 5 w / w% pregelatinized starch (SWELSTAR WB-1; Asahi Kasei) aqueous solution and 7.00 kg of water are used as a binder. In addition, granulation was performed.
Levofloxacin hydrate 11.993kg
Crystalline cellulose 1.065kg
Carboxymethyl starch sodium (primogel) 3.042kg
Sodium stearyl fumarate 0.316 kg
The granulated product was dried with a fluidized bed dryer (Paurec WSG-30). This operation was repeated three times, and the sub-batch was collected into a dry product. 1.87 mg of powdered sodium stearyl fumarate obtained by sizing the dried product was added to 100 mg of the powder, mixed and compressed into tablets, and the diameter was 3.1.
About 49 kg of levofloxacin hydrate minitablets with a thickness of 3.1 mm were obtained.

(iv) Production of valacyclovir hydrochloride-containing mini-tablet (uncoated tablet D):
The following components are weighed, put into a stirring and mixing granulator (high speed mixer) and mixed, and a 6.4 w / w% pregelatinized starch (SWELSTARWB-1; Asahi Kasei) aqueous solution 1 as a binder.
00g was added and granulated.
Valacyclovir hydrochloride 178.0g
Crystalline cellulose 10.2 g
Carboxymethyl starch sodium (primogel) 32.0 g
Sodium stearyl fumarate 4.3g
Powder 19 obtained by drying the granulated product with a fluidized bed dryer (Paurec MP-01) and adjusting the size.
Add 3.6 g of sodium stearyl fumarate to 7.6 g, mix and compress to 3.1 m diameter
m Thickness 3.1mm Valacyclovir Hydrochloride Mini Tablets About 24mg / Tablet 177.7g
(About 7,400 tablets).

(v) Production of valacyclovir hydrochloride-containing mini-tablet (uncoated tablet E):
The following components were weighed, added to a stirring and mixing granulator (Paurek VG-25), mixed, and 6 w / w% pregelatinized starch (SWELSTAR WB-1; Asahi Kasei) aqueous solution 1 as a binder
000 g was added and granulated.
Valacyclovir hydrochloride 2224g
Partially pregelatinized starch (PCS) 136g
400g sodium carboxymethyl starch (primogel)
Talc 80g
The granulated product is dried with a fluidized bed dryer (Paurec MP-01) and then granulated, and 1.38 mg of sodium stearyl fumarate is added to 100 mg of the powder, mixed, and compressed into tablets. 2700 g of valacyclovir hydrochloride mini-tablet with a thickness of 3.1 mm was obtained.

(Vi) Production of valacyclovir hydrochloride-containing mini-tablet (uncoated tablet F):
The following components were weighed, added to a stirring and mixing granulator (Paurec VG-25), mixed, and 6 w / w% pregelatinized starch (SWELSTAR WB-1; Asahi Kasei) aqueous solution 7 as a binder
50g was added and granulated.
Valacyclovir hydrochloride 2224g
Partially pregelatinized starch (PCS) 536g
Talc 80g
The granulated product is dried with a fluidized bed dryer (Paurec MP-01) and then sized, and 1.38 mg of sodium stearyl fumarate is added to 100 mg of the powder, mixed, and compressed into tablets, and the diameter is 3.1 mm. About 2600 g of valacyclovir hydrochloride mini-tablet with a thickness of 3.1 mm was obtained.

(Vii) Production of valaciclovir hydrochloride-containing mini-tablet (uncoated tablet G):
The following components were weighed, added to a stirring and mixing granulator (Paurec VG-25), mixed, and 6 w / w% pregelatinized starch (SWELSTAR WB-1; Asahi Kasei) aqueous solution 7 as a binder
50g was added and granulated.
Valacyclovir hydrochloride 2224g
Partially pregelatinized starch 551g
Talc 80g
The granulated product is dried with a fluidized bed dryer (Paurec MP-01) and then sized, and 1.38 mg of sodium stearyl fumarate is added to 100 mg of the powder, mixed, and compressed into tablets, and the diameter is 3.1 mm. About 2700 g of valacyclovir hydrochloride mini-tablet with a thickness of 3.1 mm was obtained.

Table 1 shows the formulations of uncoated tablets A to G (each component content when the active component content is 500 mg).

Examples 1-2
After mixing concentrated glycerin with ethanol, HPC (HPC-L; Nippon Soda, display viscosity: 6 to
10 mPa · s) was added and dissolved. HPMC (TC-5E; Shin-Etsu Chemical, indicated viscosity: 3 mP
a)) and carboxyvinyl polymer (Carbopol 971P; Lubrizol A)
advanced Material Inc. , Display viscosity: 6420 mPa · s) was sequentially added and dispersed uniformly. Furthermore, erythritol (Mitsubishi Corporation Food Tech), xanthan gum (K
eltrol CG-T; tricrystal, indicated viscosity: 1555 mPa · s) was pulverized with a jet mill (Seishin Enterprise SJ-3) and then added and dispersed uniformly. Finally, a solution obtained by dissolving calcium chloride dihydrate in ethanol was added and uniformly dispersed to obtain a coating solution. This coating solution was spray coated onto the uncoated tablet A using a coating apparatus (Paurec Doria Coater 200) to obtain a coated mini tablet (coating ratio: about 10% by mass ratio with respect to the coated mini tablet). 140g uncoated tablet in one coating (
About 5,833 tablets).
In addition, as Examples 1-P and 2-P, coated mini-tablets were obtained by the same adjustment method as in Examples 1 and 2 except that uncoated tablet P was used instead of uncoated tablet A (140 g uncoated tablet,
About 5,833 tablets).

Example 3
In the coating liquid preparation method of Example 1, HPC-L was not added, and the coating minitablet was obtained by the preparation method according to Example 1.

Example 4
A coating minitablet was obtained by the same preparation method as in Example 1, except that Carbopol 974P (Lubrizol Advance Material Inc., display viscosity: 32850 mPa · s) was used instead of Carbopol 971P in the coating liquid preparation method of Example 2. It was.

Example 1-1
A coated mini-tablet was obtained by the preparation method according to Example 1 except that mannitol (Mannit P; Mitsubishi Corporation Foodtech) pulverized with a jet mill was used instead of erythritol in the coating liquid preparation method of Example 1.

Example 1-2
HPMC was not added in the coating liquid preparation method of Example 1, and the coating minitablet was obtained by the preparation method according to Example 1 after that.

Example 1-3
A coated mini tablet was obtained by the preparation method according to Example 1 except that HPMC was not added and the amount of erythritol was increased in the coating liquid preparation method of Example 1.

Example 1-4
A coating minitablet was obtained by the preparation method according to Example 1 except that the amount of carbopol 971P was increased and the amount of erythritol was decreased in the coating liquid preparation method of Example 1.

Example 1-5
A coated mini tablet was obtained by the preparation method according to Example 1, except that erythritol was not added and HPMC was increased in the coating liquid preparation method of Example 1.

Example 2-1
In the coating liquid preparation method of Example 1, Carbopol 971P was not added, and the coating minitablet was obtained by the preparation method according to Example 1.

Example 2-2
In the coating liquid preparation method of Example 1, xanthan gum was not added, and the coating minitablet was obtained by the preparation method according to Example 1.

Comparative Example 1
As Comparative Example 1, uncoated tablet A obtained by producing the levofloxacin hydrate mini-tablet was used.

Comparative Example 2
A normal film-coated mini tablet was prepared for the purpose of light shielding and bitterness masking. After dissolving HPMC and Macrogol 6000 (Wako Pure Chemical Industries) in water, talc (Matsumura Sangyo),
Titanium oxide (Freund Sangyo) was uniformly dispersed to obtain a coating solution. This uncoated tablet P or uncoated tablet A was coated with this coating solution using a coating apparatus (Paurec Doriaco-200) to obtain a coated mini tablet (coating ratio: about 10% by mass ratio with respect to the coated mini tablet).

Comparative Example 3
In the coating liquid preparation method of Example 1, HPMC and calcium chloride dihydrate were not added, but mannitol (Mannit P; Mitsubishi Corporation Foodtech) pulverized by a jet mill was used instead of erythritol pulverized by jet mill. A coated mini-tablet was obtained by the preparation method according to Example 1.

Table 2 shows the coating liquid formulations (parts) of Examples 1-4, 1-1-2-2 and Comparative Examples 2-3.

Example 5
After macrogol 6000 is dissolved in water, a coating solution (seal coating solution formulation I) in which HPMC (TC-5R; Shin-Etsu Chemical) is dissolved is spray-coated on the uncoated tablets C140g using a coating device (Paurec Doria Coater 200). Thus, a seal-coated mini-tablet was obtained (coating rate: about 4% by mass ratio with respect to the seal-coated mini-tablet). Next, HPC (HPC-L; Nippon Soda, indicated viscosity: 6 to 10 mPa · s) was added to ethanol and dissolved, followed by HPMC (TC-5E; Shin-Etsu Chemical) and carboxyvinyl polymer (Carbopol 971P; Lubrizol Advanced Mat).
erial Inc. , Display viscosity: 6420 mPa · s) was sequentially added and dispersed uniformly. Furthermore, erythritol (Mitsubishi Corporation Foodtech), xanthan gum (KeltrolCG-T)
Tricrystals, indicated viscosity: 1555 mPa · s) were pulverized with a jet mill (Seishin Enterprise SJ-3) and then added in order and dispersed uniformly. Finally, a solution obtained by dissolving calcium chloride dihydrate in ethanol was added and uniformly dispersed to obtain an overcoating solution. This overcoating solution was spray-coated on the above-mentioned seal coating mini-tablet using a coating apparatus (Paure Doria Coater 200) to obtain a coating mini-tablet (coating ratio: about 8% by mass with respect to the coating mini-tablet).

Example 6
In the method for preparing the overcoating solution of Example 5, the coating mini was prepared by the same method as in Example 5 except that reduced maltose starch syrup (Amalty MR-100; Mitsubishi Corporation Foodtech) was used instead of erythritol. I got a tablet.

Example 7
A coated mini-tablet was obtained by the preparation method according to Example 5 except that trehalose (Trehalose S; Asahi Kasei Chemicals) pulverized with a jet mill was used instead of erythritol in the overcoating liquid preparation method of Example 5.

Example 8
The same method as in Example 5 except that guar gum (guar gum RG100; MR Polysaccharide, display viscosity: 1100 mPa · s) pulverized with a jet mill was used instead of xanthan gum in the overcoating liquid preparation method of Example 5. A coated mini tablet was obtained.

Example 9-1
A coated mini-tablet was obtained by the preparation method according to Example 5, except that sodium alginate (Kimika Argin I-8; Kimika) ground by a jet mill was used instead of xanthan gum in the overcoating liquid preparation method of Example 5.

Example 9-2
A coated mini-tablet is obtained by the preparation method according to Example 5 except that sodium alginate (Kimika Argin I-8; Kimika) pulverized with a jet mill is used instead of the carboxyvinyl polymer in the method for preparing the overcoating liquid of Example 5. It was.

Example 10
A coated mini-tablet was obtained by the preparation method according to Example 5 except that uncoated tablet A was used instead of uncoated tablet C in Example 5.

Example 11
A coated mini-tablet was obtained by the preparation method according to Example 5 except that uncoated tablet B was used instead of uncoated tablet C in Example 5.

Example 12
About 2 kg of the same uncoated tablet C as in Example 5 is spray-coated with a seal coating liquid (seal coating liquid formulation I) having the same composition as in Example 5 using a coating apparatus (Paurec coater 7) to obtain a seal-coated mini tablet. (Coating rate: about 4% by weight with respect to the seal-coated mini-tablet). Next, sucralose and HPC (HPC-L; Nippon Soda) were added to ethanol and dissolved, followed by HPMC (TC-5E; Shin-Etsu Chemical).
And carboxyvinyl polymer (Carbopol 971P; Lubrizol Advance)
ed Material Inc. , Display viscosity: 6420 mPa · s) was sequentially added and dispersed uniformly. Furthermore, erythritol (Mitsubishi Corporation Food Tech), xanthan gum (Keltro)
l CG-T; Tricrystal, display viscosity: 1555 mPa · s)
After pulverization in SJ-3), the mixture was added in order and dispersed uniformly. Finally, a solution obtained by dissolving calcium chloride dihydrate in ethanol was added and uniformly dispersed to obtain an overcoating solution. This overcoating solution was spray coated on the above-mentioned seal coating mini-tablet using a coating apparatus (Paurec coater 7) to obtain a coating mini-tablet (coating ratio: 4.5% by mass ratio with respect to the coating mini-tablet).

Example 13
Spray coating of a seal coating liquid (seal coating liquid formulation I) of the same composition as in Example 12 on about 50 kg of the same uncoated tablet C as in Example 12 using a coating apparatus (Paurec coater 150), Obtained (coating rate: about 4% by mass ratio with respect to seal-coated mini-tablets). Next, an overcoating solution having the same composition as that of Example 12 was spray-coated on the above-mentioned seal-coated mini-tablet using a coating apparatus (Paurec coater 150) to obtain a coated mini-tablet (coating ratio: mass relative to the coated mini-tablet). Ratio 4.5%).

Comparative Example 4
As Comparative Example 4, the uncoated tablet C was used.

Comparative Example 5
As Comparative Example 5, the seal coating mini-tablet prepared in Example 5 was used.

Comparative Example 6
As Comparative Example 6, uncoated tablet D was used.

Table 3 shows the uncoated tablets, seal coating, and overcoating solution formulations (parts) used in Examples 5 to 8, 9-1 to 9-2, 10 to 13 and Comparative Examples 4 to 5. Table 4 shows the formulations (numbers) of seal coating solutions and middle coating solutions coated in Examples 5 to 23 and Comparative Examples 5 to 6. The coating rate (%) in Table 3 is determined as follows.

Seal coating ratio (%) = (mass of 100 tablets after seal coating−mass of 100 tablets) / mass of 100 tablets after seal coating × 100

Overcoating coating ratio (%) = (mass of 100 tablets after overcoating−mass of 100 tablets of overcoated) / mass of 100 tablets after overcoating × 100

(Note that each tablet weight is a moisture correction value)

Example 14
A coated mini tablet was obtained by the preparation method according to Example 5 except that uncoated tablet D was used instead of uncoated tablet C in Example 5. The coating ratio of the overcoating was 5.0% by mass ratio with respect to the coated mini tablet.

Example 15
After dissolving erythritol in water, pregelatinized starch (SWELSTAR WB-1; Asahi Kasei)
The coating solution in which the solution was dissolved was spray-coated on about 2 kg of the uncoated tablet E using a coating apparatus (Paurec coater 7) to obtain a seal coating mini-tablet (seal coating solution formulation IV, coating rate: against the seal coating mini-tablet (4.9% by weight). Next, sucralose and HPC (HPC-L; Nippon Soda) were added to ethanol and dissolved, followed by HPMC (TC-5E; Shin-Etsu Chemical) and carboxyvinyl polymer (Carbopol 971P; Lubrizol Advanced Material In).
c. , Display viscosity: 6420 mPa · s) was sequentially added and dispersed uniformly. Furthermore, erythritol (Mitsubishi Corporation Foodtech) and xanthan gum (Keltrol CG-T; tricrystal, display viscosity: 1555 mPa · s) were pulverized sequentially with a jet mill (Seishin Company SJ-3) and dispersed uniformly. Finally, a solution obtained by dissolving calcium chloride dihydrate in ethanol was added and uniformly dispersed to obtain an overcoating solution. This overcoating solution was spray-coated on the above-mentioned seal coating mini-tablet using a coating apparatus (Paurec coater 7) to obtain a coating mini-tablet (coating ratio: about 5% by mass ratio with respect to the coating mini-tablet).

Example 16
A coated mini-tablet was obtained by the preparation method according to Example 15 except that the amount of pregelatinized starch was reduced and the amount of erythritol was increased (seal coating formulation V) in the seal coating solution preparation method of Example 15.

Example 17
In the seal coating solution preparation method of Example 15, the seal coating solution formulation I was used instead of the seal coating solution formulation V, and the addition amounts of carboxyvinyl polymer, calcium chloride and HPC-L were reduced in the overcoating solution preparation method, and sucralose A coated mini tablet was obtained by the preparation method according to Example 15 except that was added.

Example 18
Example 17 except that light anhydrous silicic acid was added in the seal coating solution preparation method of Example 17 (Seal coating solution formulation II), and the coating rate was reduced to 3.0% by mass ratio with respect to the coated mini-tablet in overcoating. A coated mini-tablet was obtained by a preparation method according to the above.

Example 19
A preparation method according to Example 18 except that uncoated tablet F was used instead of uncoated tablet E of Example 18 and talc was used instead of light anhydrous silicic acid in the seal coating preparation method (Seal coating solution formulation III). A coated mini tablet was obtained.

Example 20
Except that uncoated tablet F was used in place of uncoated tablet E of Example 18, the coating rate of the seal coating was increased, and the amount of carboxyvinyl polymer added and the coating rate of the overcoating were increased in the overcoating solution preparation method. A coated tablet was obtained by the preparation method according to Example 18.

Example 21
In the method of preparing the seal coating solution, using uncoated tablet G instead of uncoated tablet F of Example 18,
Example except that HPMC was changed from TC-5R to TC-5E having a lower viscosity, erythritol was added instead of Macrogol 6000 and light silicic acid, and ethanol was further added to the solvent (seal coating formulation VI). A coated mini tablet was obtained by the preparation method according to No.18.

Example 22
The coating rate of the seal coating of Example 21 was increased, and a coated tablet was obtained by the preparation method according to Example 21 except that the amount of carboxyvinyl polymer added and the coating rate of the overcoating were increased in the overcoating liquid preparation method. It was.

Example 23
After dissolving HPMC (TC-5R; Shin-Etsu Chemical) in a mixture of water and ethanol (35:15),
Spray coating the coating liquid (seal coating formulation VIII) in which talc is dispersed to about 5 kg of the uncoated tablet G using a coating apparatus (Paurec coater 7)
A seal-coated mini-tablet was obtained (coating rate: 3.0% by mass with respect to the seal-coated mini-tablet). Next, a coating solution (middle coating formulation VIII) in which erythritol is dissolved in water is applied to a coating apparatus (Paurec coater 7).
) To obtain a middle-coated mini tablet (coating rate: 3.0% by mass with respect to the middle-coated mini tablet). After sucralose and HPC (HPC-L; Nippon Soda) were added to ethanol and dissolved, HPMC (TC-5
E; Shin-Etsu Chemical) and carboxyvinyl polymer (Carbopol 971P; Lubrizo)
l Advanced Material Inc. , Display viscosity: 6420 mPa · s) was sequentially added and dispersed uniformly. Furthermore, erythritol (Mitsubishi Corporation Foodtech), xanthan gum (Keltrol CG-T; tricrystal, display viscosity: 1555 mPa · s) was jet milled (
After pulverization with Seishin company SJ-3), it was added in order and dispersed uniformly. Finally, a solution obtained by dissolving calcium chloride dihydrate in ethanol was added and uniformly dispersed to obtain an overcoating solution. This overcoating solution was spray-coated on the above-mentioned middle-coated mini tablet using a coating apparatus (Paurec coater 7) to obtain a coated mini-tablet (coating ratio: 4.0% by mass ratio with respect to the coated mini-tablet).

Comparative Example 6
As Comparative Example 6, the uncoated tablet D was used.

Table 5 shows the uncoated tablets, seal coating formulation, and overcoating solution formulation (number of copies) used in Examples 14 to 23 and Comparative Example 6. Moreover, the coating rate (%) in Table 5 is
It was obtained as follows.

Seal coating ratio (%) = (mass of 100 tablets after seal coating−mass of 100 tablets) / mass of 100 tablets after seal coating × 100

Middle coating ratio (%) = (mass of 100 tablets after middle coating−mass of 100 tablets coated with seal) / mass of 100 tablets after middle coating ×
100

Coating ratio of overcoating (%) = (mass of 100 tablets after overcoating−mass of 100 tablets of seal-coated or middle-coated tablets) / mass of 100 tablets after overcoating × 100

(Note that each tablet weight is a moisture correction value)

Reference example 1
A prescription liquid was prepared according to the liquid A described in Production Example 1 of Patent Document 4. That is, purified water 55.
0 g was taken, and 3.0 g of polyvinyl alcohol saponified product (Wako Pure Chemical Industries, Ltd.) was slowly added thereto with stirring, and the mixture was completely dissolved by stirring for about 1 hour while heating to 70 ° C. Similarly, 45.0 g of purified water was taken, and 1.0 g of Carbopol 974P was slowly added thereto while stirring, and stirred for about 30 minutes for complete dissolution. These two solutions were combined and stirred thoroughly. The solution obtained at this point is very viscous even though polyacrylic acid is not crosslinked because calcium chloride is not added, and cannot be spray coated using the spray coating apparatus described in Example 1. It was. Accordingly, it was estimated that it was difficult to perform spray coating using a solution in which polyacrylic acid was crosslinked by calcium ions generated by further adding calcium chloride and ionizing calcium chloride.

Reference example 2
An inner layer coating solution was prepared according to Reference Example 1 except that 0.33 g of glycerin was added to the formulation of Reference Example 1 and the total amount of purified water added was 250 g. 2. 170 g of purified water, 1.0 g of glycerin, polyvinylpyrrolidone (PVPK-90, ISP Japan Ltd.)
5 g, 0.5 g of calcium chloride and 0.5 g of xanthan gum (Keltrol CG-T; tricrystal, indicated viscosity: 1555 mPa · s) were slowly added with stirring, and the mixture was completely stirred for about 30 hours while heating to 70 ° C. And the outer layer coating solution was prepared.
The inner layer coating solution was spray coated on the uncoated tablets P using a coating apparatus (Paurec Doria Coater 200) and dried, and then the outer layer coating solution was spray coated in the same manner to obtain a coated mini tablet. Although the coating was carried out in two portions, the total coating amount of the inner layer coating and the outer layer coating remained at a mass ratio of about 4.3% with respect to the mini-tablet.

Test Example 1 (Evaluation of slipperiness)
A silicon tube (8 × 12: inner diameter 8 mm, outer diameter 12 mm) was cut to a length of 5 cm and fixed vertically to the aluminum block with an adhesive tape. The lower end was capped with absorbent cotton (25-30 mg), and 20 mini tablets were tapped from above. Pass 5 mL of water into the silicone tube with a syringe, and immediately insert the probe (spherical probe with a diameter of 6 mm) set in the texture analyzer (TA-XT-Plus) manufactured by Stable Micro Systems into the tube. It was moved 40 mm at a speed of 8 mm / sec and the stress at that time was measured.

Test Example 2 (Evaluation of bitterness masking)
Stand up a 2.5 mL plastic syringe vertically, pack about 27-30 coated mini tablets (500 mg as levofloxacin or valacyclovir) containing levofloxacin hydrate or valacyclovir hydrochloride, and add 2 mL / mL of water heated to 37 ° C from the top min
It was dripped at the flow rate of. The solution was dropped for 30 seconds or 2 minutes, and the liquid flowing out from the mouth of the syringe was collected, and the concentration of levofloxacin hydrate or valacyclovir hydrochloride was measured.

Test Example 3 (Evaluation of dissolution)
About 27-30 coated mini tablets containing levofloxacin hydrate or valacyclovir hydrochloride (500 mg as levofloxacin or valacyclovir) were tested by the Japanese Pharmacopoeia dissolution test paddle method (test solution: Japanese Pharmacopoeia Disintegration Test Solution 1 (Liquid, rotation speed: 50 rotations) The dissolution rate 30 minutes after the start of the test was measured.
Test results are shown in Tables 6-8.

Evaluation result by Test Example 1 (Evaluation of slipperiness)
In Comparative Example 1 (Uncoated Tablet A), Comparative Example 2 (Uncoated Tablet A is an ordinary film coating) and Comparative Example 3 containing carboxyvinyl polymer and xanthan gum but not containing a polyvalent metal salt, maximum stress and stress-distance curves The lower area showed a large value, and it was estimated that sliding on the mucous membrane was bad and it was difficult to swallow. In Comparative Example 3, it was considered that the result was that the carboxyvinyl polymer was not crosslinked by the polyvalent metal ion because the polyvalent metal ion was not generated by water. Examples 1-4 and 1-1 comprising a carboxyvinyl polymer, a polyvalent metal salt and xanthan gum
In ˜1-5, the stress was 41 g or less and the value of the area under the stress / distance curve was 516 g · mm or less, and it was estimated that swallowing was easy.
Examples 6 and 7 containing reduced maltose starch syrup or trehalose instead of erythritol
Examples 8,9-1 containing guar gum or sodium alginate instead of xanthan gum
In Example 9-2 containing sodium alginate instead of carboxyvinyl polymer, the maximum stress and the area under the stress / distance curve were small, and it was assumed that swallowing was easy.
Moreover, the slipperiness of Examples 1-P and 2-P was equivalent to that of Examples 1 and 2, respectively. From this, it was confirmed that if the shape of the uncoated tablet and the coating of the present invention are the same, the same slipperiness effect can be obtained even if the composition of the uncoated tablet is different.
Moreover, the coating mini-tablet obtained in Reference Example 2 was slightly gelled by adding water. However, the maximum stress is 62.7 g and the area under the stress / distance curve is 786 g.
-Mm, which is a large value compared to the examples of the present invention, and it was estimated that sliding on the mucous membrane was poor and that it was difficult to swallow.
In the examination after Example 5, seal coating was performed, but the influence on the measured value of the seal coating was hardly observed. In combination with the results of the uncoated tablets, it was estimated that the slipperiness can be improved by applying the coating of the present invention to the outermost layer of the tablets having various surface properties.
As shown in Examples 12, 13, and 15-23, even when sucralose was added to the coating solution, good slipperiness could be achieved.
In Tables 7 and 8, ○ in the maximum stress column indicates that the stress is 41 g or less, and ○ in the area under the stress / distance curve indicates that the area under the stress / distance curve is 516 g · mm or less.

Evaluation by Test Example 2 (Evaluation of bitterness masking)
In Comparative Example 1 (Uncoated Tablet A) and Comparative Example 2 (Normal Film A coated on Uncoated Tablet A), the concentration of levofloxacin hydrate in the effluent is significantly higher than other formulations when water is dropped for 2 minutes. The value is shown. Although the density | concentration of the comparative example 2 became low compared with the comparative example 1, it was thought that it was inadequate as a masking effect. In Examples 1 to 4 and 1-1 to 1-5 containing carboxyvinyl polymer, polyvalent metal salt and xanthan gum, the eluate concentration was 3 μg / m when water was dropped for 2 minutes.
L or less, and is considered to have a good bitter taste masking effect. From these results, it became clear that a high bitterness masking effect can be obtained by combining carboxyvinyl polymer and xanthan gum.
Further, in the examination after Example 5, the coating amount of the overcoating solution was lowered, but in the case of levofloxacin hydrate, the concentration of the eluate was 50 μg / mL or less when water was dropped for 30 seconds. It was. In Examples 5 to 9-2 and Examples 12 and 13 in which uncoated tablet C containing levofloxacin hydrate was overcoated, the drug concentration in the effluent compared to Comparative Example 5 (uncoated tablet C only with seal coating) Shows a low value of about 1/180 to 1/3, and in Examples 14 to 23 in which any of uncoated tablets D to G containing valacyclovir hydrochloride was overcoated, Comparative Example 6 (Uncoated tablet D was coated with seal) The drug concentration in the effluent is 1/6000 to 1/100 (for example, the drug concentration in the effluent is about 1/360 compared to Comparative Example 6 in Example 14), In each overcoating, a practically sufficient masking effect was confirmed. Furthermore, in Examples 12, 13 and Examples 15 to 23 to which sucralose was added, it was expected that the unpleasant taste masking effect was further improved.
The drug concentrations in the effluents of Comparative Examples 2 and 5 in which only the seal coating was applied to the uncoated tablets were lower values of about 1/15 and about 1/20 than those of Comparative Examples 1 and 4 which were the uncoated tablets. Indicated. This is because the combination of the overcoating of the present invention and the seal coating enhances the unpleasant taste masking effect at the time of taking, and / or components such as an unpleasant taste component of the drug core are stored in the overcoating layer during storage. It was thought that the effect of preventing the movement and preventing the compounding change of the drug core component and the overcoating layer component and the attenuation of the masking effect were exhibited.
In particular, Example 23, which combines the overcoating, middle coating, and seal coating of the present invention, has a lower drug concentration in the effluent than other examples, which combine the overcoating and middle coating of the present invention. As a result, a high masking effect of unpleasant taste was confirmed.
In Table 7, ○ in the effluent concentration column for 30 seconds represents an eluate concentration of 50 μg / mL or less,
In Table 8, ◯ in the effluent concentration column for 30 seconds represents an eluate concentration of 60 μg / mL or less.

Evaluation results according to Test Example 3 In Comparative Examples 1 and 2, the elution rate was extremely high. Examples 1 to 3 containing HPMC and sugar alcohol
4. In Example 2-1, which did not contain carbopol and contained xanthan gum, HPMC and erythritol, the elution rate for 30 minutes was 80% or more, and excellent elution was exhibited. In Example 2-2 using only carbopol as the thickener, the dissolution rate was 70% or more. From the results of Example 1 and Example 1-4, it was found that elution delay did not occur when the content of carbopol in the film was 12%, but slightly increased when the content was increased to 16% by mass.
From the results of Examples 5 to 7, it was found that even when erythritol was replaced with maltitol (reduced maltose starch syrup) or trehalose, excellent elution was exhibited.
In the study after Example 5, the coating amount of the overcoating solution was lowered, but practically sufficient dissolution rate was exhibited in all the formulations after Example 5, and the difference in the formulation of the uncoated tablet or the seal There was no effect of coating.
In Tables 7 and 8, the 30 minute dissolution rate column indicates that the 30 minute dissolution rate is 80% or more,
○ represents an elution rate of 30 minutes for 60% or more.

As described above, in the oral composition of the present invention, the surface of the tablet is quickly gelled by a small amount of water or saliva, the tablets are easy to gather, and the mucosa is easily slipped and swallowed. Also,
The gelled coating film shows an unpleasant taste masking effect by suppressing drug elution for a short time until swallowing, and the film disintegrates rapidly after swallowing and does not affect drug outflow.

Claims (1)

Invention described in the specification.